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ABSTRACT
A NOVEL FIBROBLAST GROWTH FACTOR 1 VARIANT REVERSES
NONALCOHOLIC FATTY LIVER DISEASE IN TYPE 2 DIABETES
Qian Lin
August 2, 2018

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder
and is strongly associated with type 2 diabetes (T2D). Our recently engineered FGF1
partial agonist, carrying triple mutations (FGF1△HBS) exhibits greatly reduced proliferative
potential, while preserving the full metabolic activity of wild-type FGF1. This study tests
the preventive and therapeutic effects of FGF1△HBS on NAFLD in db/db T2D and explores
potential mechanisms. The results showed that administration of FGF1△HBS to 2-monthold db/db mice for 2 months constantly lowered blood glucose levels, improved insulin
sensitivity, and lowered liver weight, lipid deposition, and inflammation, along with
improvement of liver function. Simultaneously, FGF1△HBS treatment prevented diabetesinduced hepatic oxidative stress along with promoting nuclear translocation of the
antioxidant transcription factor Nrf2 and elevating its downstream antioxidant genes. In
addition, FGF1△HBS administration inhibited the activity and/or expression of hepatic
lipogenic genes including SREBP-1, FAS and SCD-1. Furthermore, FGF1△HBS treatment
rescued hepatic fatty acid oxidation signaling, including elevated expressions of CPT-1α,
PPARα and PGC-1α. Moreover, FGF1△HBS treatment greatly increased hepatic

iv

phosphorylation of the key energy sensor AMPK, along with upregulating its downstream
genes ACC and SREBP-1 phosphorylation, indicating that FGF1△HBS regulation of hepatic
lipid metabolism is associated with AMPK signaling pathway. Mechanistically, hepatic
cells treated with palmitate (Pal) mimicked the diabetic phenotype of hepatic oxidative
damage and lipid disorder seen in db/db mice, all of which could be reversed by
supplementing with FGF1△HBS. Knockdown of Nrf2 by SiRNA completely abolished the
anti-oxidative capacity of FGF1△HBS but did not affect the beneficial effects of FGF1△HBS
on Pal-induced lipid metabolic disorder. Whereas, AMPK knockdown by SiRNA
completely abolished FGF1△HBS ability to prevent Pal-induced hepatic lipotoxicity and
SREBP-1-mediated lipid metabolic disorder, along with inhibiting Nrf2-mediated
antioxidative signaling pathway. Most importantly, administration of FGF1△HBS to 9-monthold db/db mice for 3 months completely reversed the phenotype of NAFLD along with
activation on Nrf2 and AMPK signaling pathways.
Our findings demonstrate that, in addition to its potent glucose-lowering and insulinsensitizing effects, FGF1ΔHBS can reverse NAFLD in T2D, by its ability to upregulate AMPK
to activate Nrf2-mediated antioxidative pathway and inhibit SREBP-1-mediated lipid
metabolic pathway.

Keywords: Fibroblast growth factor 1, nonalcoholic fatty liver disease, oxidative
stress, AMP-activated protein kinase, nuclear factor erythroid 2-related factor 2, sterol
regulatory element-binding protein
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OVERVIEW

FGF superfamily and FGF1 subfamily
Fibroblast growth factors (FGFs) family contains 22 members that are found in
organisms ranging from the nematodes to humans. Based on the differences in sequence
homology and phylogeny, these 22 members are commonly grouped into 7 subfamilies:
FGF1 subfamily (FGF1 and FGF2); FGF7 subfamily (FGF3, FGF7, FGF10, FGF22); FGF4
subfamily (FGF4, FGF5 and FGF6); FGF8 subfamily (FGF8, FGF17 and FGF18); FGF9
subfamily (FGF9, FGF16 and FGF20); and FGF15/19 subfamily (FGF19, FGF21 and
FGF23); and FGF11 subfamily (FGF11,FGF12, FGF13 and FGF14)(1, 2). Among all these,
the FGFs with low heparin-/heparan sulfate-binding capacities showing the increased
diffusion from their source are defined as endocrine FGF ligands (FGF19, FGF2 and
FGF23). Intracellular FGF ligands (FGF11 to FGF14) are not extracellularly secreted and
perform an intracrine manner to involve in regulating the electrical excitability in neurons.
The remaining FGFs are the paracrine FGFs ligands that have high affinity for heparan
sulfate glycosaminoglycan (HSGAG), which lead them to perform a localized manner near
the sources of their expressions. The FGF1 subfamily includes FGF1 and FGF2, which is
often called the “prototypical” FGF since they were the first of the FGFs to be isolated and
identified around 1975(3).

FGF1 gene and gene products
Fibroblast growth factor 1 (FGF1), also known as acidic fibroblast growth factor
(aFGF), is a growth factor and signaling protein encoded by the FGF1 gene. The murine
1

and human FGF1 were identified and characterized at the cDNA level in the early 90s.
The murine gene locates on chromosome 18, and is encoded by a single copy gene,
which spans over 30 kb of genomic sequence. FGF1 mouse recombinant protein
produced in E. Coli is a non-glycosylated and single polypeptide chain that contains 161
amino acids (16-155 a.a) with the molecular mass about 18kDa(4, 5). The human FGF1
gene resides on chromosome 5q31, which spans over 100 kb. FGF1 human recombinant
protein produced in E. Coli is also a non-glycosylated and single polypeptide chain that
contains 140 amino acids with the molecular mass of approximately 15.8kDa. While the
mature form of human FGF1 is synthesized as a polypeptide of 155 amino acids, with the
molecular mass about 17-18 kDa. The mouse FGF1 genomic organization is very similar
to that of human, since both genes are comprised of three protein coding exons of sizes
203, 104 and 192 bp. The sizes of the two introns are 11.4 and 4.9 kb(6). The human
FGF1 gene has a long 3’-untranslated region (3’-UTR) and a complex 5’-untranslated
region (5’-UTR). In 3’-UTR, the mouse and human FGF1 genes share 60.4% similarity in
sequence, with stretches having more than 80% similarity(7).

FGF1 receptors and their signaling
The interaction between the ligand FGFs and its receptor is responsible and essential for
the different biological activities of FGFs. FGF1 mediates biological responses by
activating and binding to the cell surface FGF receptors (FGFRs). Heparan sulfate/heparin
acts as a cofactor and is necessary for stable interactions between FGF1 and its FGFRs.
Several major FGFR proteins (FGFRs 1b, 1c, 2b, 2c, 3b, 3c, and 4) are generated from
FGFR1, FGFR2, FGFR3, and FGFR4 (FGFR1–FGFR4) genes by alternative splicing, with
differing ligand-binding specificity , respectively,

. FGF1 is considered as the universal

(8)

ligand for FGFRs due to its ability to activate and bind with each of the alternatively spliced
forms of FGFR1–FGFR4 (9, 10), in which FGFR1 is a common receptor for many ligands.
2

FGF1-FGFR-heparin ternary complex has been demonstrated to activate four key
intracellular signaling pathways that play a role in regulating the cell cycle, cell survival
and apoptosis, namely the PI3k/Akt pathway, Ras/Raf/Mek/Erk pathway, JNK and p38
MAPK pathway, and STAT3 and NF-κB pathway(11). The endocrine FGFs, such as FGF21,
FGF15/19, also act their biological regulations in an FGFR-dependent manner with the
presence of the cofactors (α-klotho or β-klotho) in their respective target tissues. The
intracellular FGFs have high sequence identity with other FGF members but do not
activate FGFRs.

The potential effects of FGF1 in diseases
FGF1 is a well characterized growth factor among the 22 members in FGF
superfamily in animals and humans. As a paracrine FGF, FGF1 is involved in the cellular
regulation of many biological processes such as cell growth, proliferation, migration,
differentiation, and survival in different cell types(12). Therefore, FGF1 is being explored for
its therapeutic potential in cardiovascular disorders, ischemia conditions, nerve injuries
and tissue repair(1). FGF1 shows angiogenic potential in improving myocardial flow,
regional and global left ventricular function and artery growth and capillary proliferation
under myocardial ischemia conditions(13-15). FGF1 can also promote nerve regeneration.
Data indicated that it enabled the functional and axonal regeneration in the transected rat
spinal cord(16, 17). FGF1 recovered the rat’s forelimb motor function after cord–root junction
transection (18). In addition, FGF1 stimulated cell proliferation and angiogenesis in vitro
and in vivo, significantly accelerating the healing of rat burn wounds(19). Although FGF1 is
a well-known mitogenic factor, the recent discoveries of metabolic roles for FGF1 in
glucose homeostasis have expanded the functions of those classically known mitogen. In
2012, Jonker and his colleagues discovered an unexpected metabolic role of FGF1. FGF1
was demonstrated to transduce of peroxisome proliferator-activated receptor gamma
3

(PPARγ) signaling that mediates the proper nutrient storage coupling in adaptive
remodeling of adipose tissue(20). In a follow-up study, this group further demonstrated that
exogenous FGF1 could stimulate the glucose uptake in an insulin-dependent fashion in
vitro and in vivo(9), much like the non-mitogenic endocrine-acting growth factor, FGF21, a
candidate drug for obesity and diabetes treatment in clinical trials(21). In recent years,
additional studies have focused on the potential of FGF1 as a treatment for diabetes and
diabetic complications. In general, the mitogenic effects of FGF1 in a variety of diseases
has been most studied and subject to the clinical trial in humans

. However, the

(14)

functions and mechanisms of its metabolic effects have been rarely clarified. To the
advantage of metabolic activity of FGF1 and expand its value inpatients, studies of
metabolic effects of FGF1 should be expanded.

The effects of FGF1 at type 1 diabetes and type 2 diabetes
Diabetes is a major and increasing metabolic disease throughout the world, which
is clinically characterized by chronic hyperglycemia because of the absolute or relative
insulin insufficiency and dysfunction(22). The treatment of diabetes is determined by the
etiopathology and is most commonly subdivided in type 1 diabetes (T1D, beta cell damage
and/or absolute lack of insulin) and type 2 diabetes (T2D, insulin resistance and/or
decreased secretion of insulin)(23).
FGF1 has not only the mitogenic activity, but also metabolic activity, representing
a potential novel anti-diabetic therapy. FGF1 was sufficient to attain normoglycemia in the
severely hyperglycemic mice, such as the genetic induced ob/ob and db/db mice, dietinduced obese (DIO) and insulin-resistant T2D mice, administered through subcutaneous
injection(9,

. However, FGF1 failed to decrease the blood glucose levels in STZ

20, 24)

induced T1D mouse model whereas pretreatment with FGF1 in STZ mice markedly
enhanced the glucose-lowering ability of exogenously supplied insulin(9). Additional
4

studies proved that FGF1 couldn’t lower blood glucose levels in STZ-induced T1D model(25,
. These results demonstrated that FGF1 might act as an insulin sensitizer. Further,

26)

intracerebroventricular (i.c.v.) injection of FGF1 also induced sustained diabetes
remission in leptin-deficient ob/ob T2D mice(24). Interestingly, i.c.v. injections of FGF1
reversed the hyperglycemia in T1D rats and promoted the insulin-independent plasma
glucose lowering effects in T1D by suppressing the hypothalamic–pituitary–adrenal (HPA)
axis(27). Taken together, the blood lowering effect of FGF1 in T2D, even in T1D, has been
studied, however, the molecular mechanism of how FGF1 protects from the disorders in
diabetes still needs further exploration.

The role of FGF1 in diabetic complications
The rising global prevalence of diabetes accompanies with an high burden of
morbidity and mortality that is attributable to the chronic hyperglycemia in the
complications, including a range of microvascular, macrovascular and metabolic
complications(28). The diabetic complications include cardiovascular disease, stroke, foot
ulcers, eye damage and chronic kidney disease, which occur in individuals with both T1D
and T2D. Current therapeutic options for controlling the chronic hyperglycemia can reduce,
but do not eradicate, the risk of these diabetic complications(29).

The effects of FGF1 on diabetic ulcers
Diabetic ulcers are responsible for a large percentage of hospitalization among the
complications of diabetes(30)，which is the major cause of nontraumatic lower extremity
amputations and disability. Moreover, the mortality of diabetic ulcer is high and healed
ulcers frequently recur(31). Diabetic ulcers occur because of various factors, such as some
intrinsic factors (hyperglycemia, vascular insufficiency and peripheral neuropathy) and
5

extrinsic factors (wound infection, callus formation and traumatic stress)(32-34). The
management of diabetic ulcers requires protecting the wound by using appropriate
footwear and antibiotic therapy, providing a moist wound environment or receiving surgical
debridement and revascularization when necessary(35,

. However, it is difficult for

36)

diabetic ulcer patients to stop scratching the wound. They can be irritated by clothing or
shoes, which increases risk for infection and increases discomfort in patients. Therefore,
an understanding the pathogenesis of diabetic ulcers and development of more effective
therapies that can enhance wound healing in diabetes is greatly needed.
FGF1 is known to exhibit mitogenic activity on various cells from different tissue
origins including skin, vasculature and liver(1, 11, 37). Many studies have demonstrated that
topical application of FGF1 stimulated the growth of new blood vessels, proliferation of
fibroblast and endothelial cells and formation of capillary, suggesting translational
potential for FGF1 in diabetic ulcers. Early studies demonstrated that FGF1 stimulated
DNA synthesis in cultured db/db mouse skin biopsy specimens and accelerated wound
closure in db/db mice at a dose-dependent manner. FGF1 decreased the median time of
wound closure from 46 d to 16 d and increased granular tissue formation, and reepithelialization throughout healing. Although wound healing in FGF1 treated diabetic
mice was slower than that in nondiabetic littermates, these studies suggest the therapeutic
potential for FGF1 in promoting healing of dermal ulcers in diabetes(38, 39). Recent studies
further confirmed that FGF1 enhanced re-epithelialization and proliferation, thereby
promoted diabetic dermal wound healing in the T2D model of NONcNZO10/LtJ mouse(40).
The wound healing effect of FGF1 on T1D has also been studied. Xie and
colleagues utilized an ulcer model in STZ-induced SD rats and topically treated the wound
surface with FGF1 for 2 weeks. Their data indicated that FGF1 improved ulcer healing on
day 7 and promoted the re-epithelialization on day 14. FGF1 treatment significantly
increased capillaries and fibroblast in the wound. This study revealed that FGF1 promoting
6

diabetic wound healing was possibly associated with enhancing the proteins expressions
of TGF-β and PCNA and preventing oxidative stress(41).
Furthermore, the modification of FGF1 with chitosan-crosslinked collagen sponge
(CCCS) or polyethylene glycol (PEGylation) was performed to improve even further the
diabetic wound healing. Both CCCS and PEGylated modified FGF1 accelerated wound
healing, collagen generation, increased the TGF-β expression, and increased dermal cell
proliferation in STZ-induced SD rats(25, 42). These results suggest that modification of FGF1
could provide a greater effective approach for the therapeutic application of native FGF1
in clinic.

The effects of FGF1 on diabetic cardiovascular disease
Diabetic cardiomyopathy (DCM) represents the leading cause of morbidity and
mortality in diabetic patients. DCM consequent to various structural and functional
changes, which is characterized by ventricular dilation, enlargement and impaired
contractility of cardiomyocytes, prominent interstitial fibrosis and diastolic and systolic
dysfunction(43, 44), eventually leading to heart failure without adequate medical treatment(45).
At present, there are no effective treatments for this common pathological condition in
DCM. Current treatments of DCM focus on intense glycemic control of the diet, oral
hypoglycemics, frequently insulin treat and heart failure symptoms management. Novel
drugs and new strategies for improving therapeutic and prognostic values in DCM are still
being explored(46).
FGF1 is regarded as the angiogenic polypeptide mitogen for cells. It has been widely
reported that FGF1 promoted the proliferation of vascular endothelial cells and smooth
muscle cells and stimulated the capillary angiogenesis and migration, and significantly
minimized infarct size, thus improving cardiac function(47-49). Recent studies have indicated
that FGF1 has beneficial effects on the heart under diabetic conditions.
7

Zhang C et al. indicated that the native FGF1 and a novel non-mitogenic FGF1 (nmFGF1) could prevent DCM by suppressing oxidative stress and cell damage. T1D mice
treated with nm-FGF1 intraperitoneally for either 1 or 6 months had no impact on body
weight and blood glucose levels as compared to non-treated diabetic mice. nm-FGF1
prevented the diabetic-induced cardiac hypertrophy by decreasing the heart weight and
the mRNA expressions of molecular hypertrophic markers (ANP, ANG and b-MHC) at 1
month and more obvious reduction at 6 months. The diabetes-induced cardiac fibrosis
(Collage content, Fibronectin and TGF- β1) were also decreased by nm-FGF1 treatment.
In vitro studies using nm-FGF1 showed similar cardiac protection as native FGF1. Both
native FGF1 and nm-FGF1 prevented the high glucose induced hypertrophy, fibrosis and
even the DNA oxidative damage in cardiac cells(50, 51). This study provided evidence for
protection of nm-FGF against DCM, implying that FGF1 might be a potential candidate for
application in DCM therapy. In a following study, Zhang M et al demonstrated an improved
FGF1 cardio-protective effect in DCM with nanoparticle modification and ultrasoundtargeted microbubble destruction technique. Similar with previous studies, this study
showed that FGF1 protected the metabolism abnormalities and myocardial interstitial
fibrosis, further preventing the left ventricle dysfunction in STZ-induced T1D rats(52, 53). In
particular, this study indicated that prevention of FGF1 against DCM could be attributed
to activating PI3K/Akt signaling pathway, in which the phosphorylated Akt reduced the
myocardial apoptosis via inhibiting the caspaes-3 activity and increasing the expression
of anti-apoptotic genes (Bax and BCL-2).
Taken together, these studies demonstrated the preclinical efficacy and
mechanisms of novel strategies for FGF1 protection against DCM.
However, it is still too limited to understand the role of FGF1 in cardiac disorders
under diabetic conditions. More specific role of FGF1 in DCM in T1D and T2D need to be
further explored.
8

The effects of FGF1 on diabetic nephropathy
Diabetic kidney disease, also known as diabetic nephropathy (DN), is the leading
cause of renal failure in patients and is a chronic complication that take place in 20% to
40% of T1D and T2D(54,

. DN is a microvascular complication in diabetics and

55)

characterized by increased glomerular basement membrane width, diffuse mesangial
sclerosis, microaneurysm, tubulointerstitial fibrosis, and vascular sclerosis. Chronic
hyperglycemia in diabetes induces dysfunction in various cell types of the kidney, which
is a risk factor for chronic kidney disease and end-stage renal disease (ESRD), leading to
progressive renal failure(56). The incidence of DN is increasing each year and a significant
number of patients who develop ESRD require renal replacement therapies(57, 58). Current
therapies for DN are aimed at controlling blood glucose and blood pressure levels,
inhibiting the renal artery stenosis and reducing or abrogating development of albuminuria
and progression of DN. However, those therapies mentioned above might not be effective
enough for DN patients who experience progressive kidney function decline resulting in
ESRD. Hence, novel therapeutic strategies are urgently needed to improve clinical
management.
Numerous growth factors and cytokines are implicated in the process of progressive
renal disease. FGF2 has been proven to involve in the pathogenesis of renal disease by
inducing the renal fibrosis(59, 60). However, the role of FGF1 in kidney disease has been
rarely studied, especially in diabetic kidney disease. Previous studies demonstrated that
FGF1 gene was expressed in the normal human kidneys but was downregulated in
kidneys from DN patients, suggesting that FGF1 might play a role in kidney function(61-63).
Recently, Huang et al demonstrated that FGF1 could protect against DN in both T1D and
T2D through an anti-inflammatory mechanism(26). Interestingly, FGF1 only significantly
decreased and maintained the blood glucose to the normal level in T2D mice. This is the

9

first study to show that the renal protective effects of FGF1 is independent of its glucoselowering effects. However, the functions and mechanism FGF1 in DN are still limited.

The effects of FGF1 on diabetic liver disease
The prevalence of liver damage in patients with diabetes is much higher than that in
the general individuals. Diabetes is strongly associated with major chronic liver diseases,
including nonalcoholic fatty liver disease (NAFLD), chronic hepatitis C (CHC),
hemochromatosis, and alcoholic liver disease (ALD)(64). Among these liver diseases,
NAFLD represents a global epidemic mainly associated with obesity, insulin resistance
and metabolic syndrome(65). In T2D patients, the prevalence of NAFLD is as high as 75%(66,
. Recent studies found that obesity also affected the clinical features of T1D, in which

67)

about 30% of patients were overweight or obese, thus increasing the susceptibility and
incidence of NAFLD in diabetes(68). NAFLD is a multifactorial disease, affecting
extrahepatic organs and regulatory pathways(69). The complex metabolic disturbances in
NAFLD increase the risk and the difficulty of treatment in diabetes(65, 70, 71).
In FGF family, the function and mechanism of FGF21 in liver diseases have been
widely studied. Unlike FGF21, FGF1 has high affinity for heparan sulfate and thus acts
locally as a mitogenic activator(72-74). The role of FGF1 in metabolic diseases has been
neglected. Recent studies draw an attention of FGF1 in liver under diabetic conditions.
Jonker et al. revealed that HFD-fed FGF1–/– mice showed severer hepatic steatosis
compared to wild-type controls(20). Furthermore, they showed that FGF1 treatment
decreased hepatic steatosis, increased the hepatic glycogen content and insulinsensitivity in DIO mice(9). These results suggest that FGF1 play a critical role in the
development of liver disease in diabetes. More recently, Liu et al showed that
administration of FGF1 effectively suppressed the hepatic inflammation in the leptindeficient ob/ob mice and the choline-deficient diet mice, two etiologically different models
10

of NAFLD. The suppression of hepatic steatosis was effectively showed in ob/ob mice,
suggesting that FGF1 could stimulate hepatic lipid catabolism. Because the antiinflammatory effects were observed in both the presence and absence of the antisteatotic
effects, these findings further suggest that the anti-inflammatory property of FGF1 is
independent of its effect on lipid catabolism. These results indicate that, in addition to its
potent glucose-lowering and insulin-sensitizing effects, FGF1 could be therapeutically
effective in the treatment of NAFLD(75). However, the mechanism of FGF1 protection
against NAFLD remains largely unknown.

The effects of FGF1 on other diabetic complications
FGF1 also involves in many other diabetic complications that has not been widely
explored. For example, diabetic retinopathy (DR) is currently the leading cause of
blindness in T1D and T2D. Lee-Anne Khuu et al observed the lower FGF1 expression in
DR patients compared to the health subjects. This study firstly demonstrated that FGF1
was associated with the decreased retinal blood flow in early DR, suggesting that FGF1
might be predisposing for diabetic vascular diseases(76). Melissa Skibba et al evaluated
the effects of nmFGF1 on the testes in STZ-induced T1D. They found that nmFGF-1
ameliorated the diabetic induction of testicular cell death by decreasing the BAX/Bcl-2
ratio and endoplasmic reticulum stress, and upregulating nuclear factor E2–related factor
2 (Nrf2) activity(77). The protective effects of FGF1 on other diabetic complications will be
warranted in future studies.

The limitation of FGF1 in diabetes
The poor stability
As the multifunctional proteins, FGFs have low thermal stability and high sensitivity
to proteases, which limit the potential pharmaceutical use of wild-type FGFs(78). In addition
11

to the powerful mitogen in numerous different cell types, FGF1 shows the locally restricted
roles in adipose tissue as well as systemic glucose-lowering activities in vivo that shows
much closely parallel to those of FGF21(9, 20). However, FGF21 is a well-characterized
endocrine FGF and circulates as a true endocrine hormone. Whereas the high affinity
heparin-/heparan sulphate proteoglycan-binding activity and serum lability of FGF1 restrict
its endogenous actions to local tissues, causing the rapid clearance of exogenous FGF1
from the systemic circulation(1). Thus, the novel FGF1 delivery system or the advanced
protein design techniques to obtain new variants of FGF1 for the increased
thermodynamic stability, prolonged half-life and improved proteolytic resistance are
necessary, which can provide promising strategies for producing therapeutic effective
FGF1.
It has been demonstrated that biopolymer encapsulation effectively sustains the
controlled release and provides a long-term delivery of growth factors(79, 80). For example,
Zhang et al used the FGF1 encapsulated nanoparticles (FGF1-NP) to treat DCM resulted
a greater preventive effect due to the improved stability of FGF1 both during storage and
in blood circulation. The preventive effects of FGF1-NP on DCM were further promoted by
using the ultrasound-targeted microbubble destruction strategy, which helped to increase
the selectivity and efficiency of FGF1-NP delivery to the heart(52,

. In addition, the

53)

conjugation of FGF1 to polyethylene glycol (PEG) (PEGylated -FGF1) or chitosancrosslinked collagen sponge (CCCS-FGF1) could prolong the release and improve the
biostability of FGF1, which had been used to accelerate the wound healing in diabetic
rats(25, 42).

Tumorigenic risk
Native FGF1 could lead to tumorigenesis, tumor invasion and metastasis, showing
great tumorigenic risk, especially in tumor latent diseases, such as diabetes(81-83). To
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decrease the potential side effects of FGF1 caused by its broad-spectrum mitogenic
activity, a non-mitogenic form of FGF1 had been developed to show decreased mitogenic
activity(50, 84). Several studies proved that this non-mitogenic FGF1 had preventive effects
on DCM and diabetic ulcer in T1D.
Recently, we have engineered a novel FGF1 variant by uncoupling the mitogenic
and metabolic functions of wild type FGF1 (FGF1WT). This FGF1 partial agonist carrying
triple mutations (FGF1△HBS) that diminished its ability to induce heparan sulfate (HS)assisted FGF receptor (FGFR) dimerization and activation. FGF1△HBS dramatically
reduced the proliferative activity, while still preserving the full metabolic activity of FGF1WT
in vitro and in vivo. Most importantly, both FGF1△HBS and FGF1WT could reverse fatty liver
in db/db mice, implying the potential of FGF1 for liver disease therapy(85).

Conclusion
FGF1 is involved in the regulation of diverse pathophysiological processes in various
metabolic syndrome. In addition to the functions of FGF1 in angiogenesis and cell
proliferation, FGF1 is also associated with the inhibition of inflammation, oxidative stress
and apoptosis in diabetic complications. Recently, the blood glucose lowering and insulinsensitizing capability of FGF1 in diabetes revealed the unexpected metabolic function of
FGF1, which expanded the functions and potential application of FGF1 in metabolic
syndrome. The following issues need to be addressed to apply FGF1 in metabolic
syndrome and its complications: 1) the mechanisms of FGF1 in metabolic syndrome; 2)
the strong mitogenic activity of FGF1 triggering high tumorigenic risk; 3) the weak stability
and low bioavailability of FGF1 under pathophysiological conditions.
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CHAPTER I
THE PREVENTIVE EFFECTS OF A NOVEL FIBROBLAST GROWTH FACTOR 1
VARIANT ON NON-ALCOHOLIC FATTY LIVER DISEASE IN TYPE 2 DIABETES

INTRODUCTION
1. Non-Alcoholic Fatty Liver Disease
As the global epidemic liver disorder, NAFLD represents a spectrum of liver disease
that ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis,
ultimately leads to the hepatocellular carcinoma (HCC) and liver failure. NAFLD is the
pathological fat accumulation in the liver without alcohol intake, that strongly linked to the
metabolic syndrome including obesity, insulin resistance, dyslipidemia and type 2 diabetes
(T2D)(69). Nowadays, the complex and strong association between of NAFLD and obesity
and T2D results to the particularly high prevalence of NAFLD in individuals with T2D,
corresponding with the worldwide increase in obesity of childhood (86). Current populationbased prevalence of NAFLD is approximately 30–40% in men and 15–20% in women(70).
NAFLD is multifactorial diseases, affecting extrahepatic organs and regulatory
pathways, in which the insulin resistance as a common pathophysiological mechanism(69).
The excess lipid accumulation in the hepatocyte due to increased inflow of free fatty acids
and de novo lipogenesis causes insulin resistance, chronic inflammation that, in turn,
contributes to further abnormal hepatic metabolism. These metabolic disturbances in
NAFLD increase the risk of progressive liver disease to fibrosis, cirrhosis and HCC, as
well as the increased risk of T2D(65). As the second hit in NASH, oxidative stress in the
liver exacerbates inflammation and hepatic fibrosis, and causes impairment of cellular
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bioenergetics, leading to further disruption of hepatic lipid metabolism and cell death(87-92).
Nowadays, there are no licensed therapies specifically for the management of NAFLD.
Current treatments for NAFLD include lifestyle management such as diet control, exercise
and behavior modification, pharmacological therapies that manage the underlying
metabolic risk factors, bariatric surgery and liver transplantation of those with end stage
liver disease(93).

2. Type 2 diabetes
Diabetes is a chronic disease that have three major types: type 1 diabetes (T1D),
T2D, and gestational diabetes. Among these types of diabetes, T2D is the most common
and prevalent diabetic diseases in the world. The latest study estimated that the worldwide
number of adult diabetes will increase by 54%, from 285 million to 439 million from 2010
to 2030, with the increasing rate in youth(94). In T2D, body cannot use the insulin properly
which leads to the insulin resistance augmented by lifestyle habits, environmental factors
and multiple genetic factors(95, 96). The increased action of insulin resistance results in high
blood glucose also called hyperglycemia. Meanwhile, hyperglycemia may deteriorate both
insulin resistance and insulin secretion abnormalities, thus enhancing the transition from
impaired glucose tolerance to diabetes(97). T2D is tightly associated with many
complications without the appropriate intervention approaches. Hyperglycemia induced
higher risk for the complications (cardiovascular disease, liver dysfunctions, retinopathy
and nephropathy) and multiple metabolic disorders (oxidative stress, inflammation and
endoplasmic reticulum stress). The long-term persistence of metabolic disorders
increases the risk development of many specific complications. Meanwhile, older diabetic
patients have a higher burden of comorbidities, diabetes-related complications, physical
disability, cognitive impairment and malnutrition, and more sensitive to the complications
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of dysglycemia and polypharmacy. These complications contribute to the excess morbidity
and mortality in older individuals with diabetes(98-103).
The prevalence of diabetes mellitus in patients with liver damage is higher compared
to that in the general population. Diabetes is strongly associated with major chronic liver
diseases, including NAFLD, chronic hepatitis C (CHC), hemochromatosis, and alcoholic
liver disease (ALD)(64). Among these liver diseases, NAFLD has been widely studied with
diabetes, especially in T2D(65). In T2D patients, the prevalence of NAFLD may be as high
as 75%(66, 67). Nowadays, there has no certain explanation for the substantial increased
risk of mortality from cirrhosis of any etiology in patients with T2D. In NAFLD, the excess
of fatty acids and impaired hepatic fatty acid oxidation exacerbate the insulin resistance,
further increase the hepatic fat accumulation. High glucose levels, obesity and insulin
resistance in diabetes may be independent factors contributing to progression of NAFLD
and the ultimate development of cirrhosis(104). These complex metabolic disturbances
between NAFLD and T2D increased risk and difficulty in treatment of NAFLD in T2D (70, 71)
.

(65)

3. The novel fibroblast growth factor 1 variant——FGF1△HBS
As introduced in the OVERVIEW, FGF1 is a well-known mitogenic factor that has
been widely studied for its therapeutic potential in cardiovascular disorders, ischemic
conditions and nerve injury(1). Interestingly, FGF1 recently showed an unexpected
metabolic function in diabetes by regulating the glucose homeostasis and insulin
sensitivity(9,

. However, FGF1 induces hyperproliferation leading to increased

20)

tumorigenic risk(105), becoming the primary obstacle for its wide application, particularly for
chronic cancer prone diseases, such as diabetes. Therefore, uncoupling of the mitogenic
and metabolic function of FGF1 could make it to be a safe and potent agent for diabetes
therapy.
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Structure-function relationship study demonstrated that paracrine FGFs, such as
FGF1, transmit their signals by binding, dimerizing and activating four FGF receptor
tyrosine kinases (FGFR1-4) in a heparin sulfate (HS)-dependent fashion(106-108); by
contrast, endocrine FGFs, such as FGF21, rely on Klotho co-receptors to bind, dimerize
and activate their cognate FGFRs(12,
.

109-112)

much

Paracrine
stronger

FGFs

facilitate

FGFRs

tyrosine

transphophorylation and intracellular
kinase domains activation via HSdependent dimerization of FGFRs
than that of endocrine FGFs via
Klotho-dependent

dimerization

of

FGFRs (113) (Fig. 1).
According to the understanding
of

the molecular

basis for

the

Fig 1. The functional differences between
paracrine and endocrine FGFs. FGF1, as a
member of paracrine FGFs, has a high affinity
with heparin sulphate as its coreceptor, which
acts in a localized manner near the source of
its expression. While the endocrine FGF,
FGF21 has β-klotho as its coreceptor with a
weak affinity with heparin sulphate leading to
increased diffusion of FGF21 from its source.

divergence in the biological activity of
paracrine and endocrine FGFs, we hypothesized that submaximal FGFR activation by a
weak endocrine FGF-FGFR dimer is sufficient to evoke a metabolic response (such as
FGF21), whereas full FGFR activation by stable and sustained paracrine FGF-FGFR
dimerization is required to elicit a mitogenic response (such as FGF1), and the mitogenic
and metabolic function of paracrine FGF1 could be uncoupled by manipulation of its HSassociated receptor dimerization. To test this hypothesis, we engineered a novel FGF1
variant, with reduced ability of inducing HS-dependent FGFR dimerization by replacing
the three key residues from the HS-binding site of FGF1, namely Lys127, Lys128 and
Lys133 with residues that are less optimal for HS binding (Lys127Asp, Lys128Gln and
Lys133Val), termed FGF1△HBS. In an initial study, we found that FGF1△HBS had significantly
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decreased receptor binding affinity compared to wild-type FGF1 (FGF1WT), which was
accompanied by significant attenuation of the proliferative potency. While FGF1△HBS
retained full metabolic activity of FGF1WT, including sensitization of insulin activity,
improvement of hepatic lipid and glucose metabolism, induction of adipose remodeling,
and prevention of diabetes-induced systemic, hepatic and adipose inflammation in db/db
mice, leading to therapeutic efficacy for T2D without mitogenic and hyperplastic activity of
FGF1WT(85).
Recent studies demonstrated that high fat diet feeding induced serve hepatic
steatosis in FGF1–/– mice compared to wild-type controls(20), while liver function and
pancreatic function appeared normal. Furthermore, FGF1 treatment decreased hepatic
steatosis and increased the insulin-stimulated Akt signaling in diet-induced obese (DIO)
mice(9) . Liu et al indicated the potent antisteatotic and anti-inflammatory effects of FGF1
on NAFLD in leptin-deficient ob/ob mice(75). In addition, our recent study indicated that
FGF1 prevented diabetic nephropathy largely via the anti-inflammatory effects in both T1D
and T2D

.

(26)

These works have brought FGF1 to the forefront as a potential new

therapeutic agent for insulin sensitization and treatment of T2D, and NAFLD therapy(114).
However, the functions and mechanism of FGF1-mediated metabolic actions in diabetic
livers remain largely unknown. To investigate the metabolic activity of FGF1 and explore
a safe treatment for NAFLD, we therefore hypothesize that the novel mitogenic and
metabolic function uncoupled variant FGF1△HBS has potential to replace the use of FGF1WT
to treat NAFLD in T2D.

MATERIALS AND METHODS
Animal models and drug administration
db/db (BKS.Cg-Dock7m +/+ Leprdb/J, Stock # 000642) mice were purchased from
Jackson Laboratory (Bar Harbor, ME). 2-month-old male db/db mice were administered
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with FGF1△HBS (0.5 mg/kg) or vehicle phosphate buffered solution (PBS) via
intraperitoneal injection every other day for 2 months. At the indicated time-points, the
blood glucose levels were determined by FreeStyle complete blood glucose monitor
(Abbott Diabetes Care Inc., Alameda, CA). All mice were housed under a 12:12-h
light/dark cycle at controlled temperature. All experimental procedures were approved by
the Institutional Animal Care and Use Committee of the University of Louisville.

Glucose-tolerance tests (GTTs)
Blood glucose levels were determined as described above. For GTTs, mice were
fasting for 9h, and then were injected with glucose solution (1 g/kg body weight)
intraperitoneally. Blood glucose levels were measured at 0, 15, 30, 60, 90, and 120 min
after glucose injection.

Biochemical analysis
Plasma ALT (Cayman Chemical, Ann Arbor, MI) and AST (BioVision, Milpitas, CA)
levels were measured using enzymatic assay kits according to the manufacturer’s
instruction. Liver TG was determined using commercially available colorimetric kits
(Thermo Scientific, Waltham, MA). Briefly, liver tissues were homogenized in 50mM NaCl
and the samples were extracted with extract reagent (Chloroform: Methanol=2:1) at 4℃
overnight. The next day, the samples were vortexed and centrifuged for 20mins, and the
lower chloroform layer were collected. Then, 500 µl of lower chloroform layer were placed
in new tubes and evaporated to dryness in the hood. The dried samples were dissolved
in TG reagent and measured with plate reader at 500nm.
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Liver histopathological analysis
Liver paraffin sections were processed as previously described(85). Liver tissues
were fixed in 10% formalin and processed to embed in paraffin. After deparaffinization and
rehydration, the paraffin sections (5μm) were subjected to hematoxylin and eosin (H&E).
oXLipid accumulation in the liver tissues was further analyzed by Oil Red O staining. For
Oil-Red-O staining, frozen sections (10μm) of liver tissues were fixed in 10% formalin for
10min and rinsed in water. Then the slides were immersed in 60% isopropanol and
incubated in Oil-Red O solution (saturated Oil Red O isopropanol solution diluted 4:6 into
60% isopropanol, Sigma-Aldrich) at room temperature for 40mins. The slides were
washed in 60% isopropanol twice. All the stained sections were quantitated for Oil-Red O
positive staining area using a Nikon Eclipse E600 microscopy system (Nikon, Tokyo,
Japan).

Quantitative determination of oxidative stress
To detect the reactive oxygen species (ROS) levels of diabetic livers after FGF1
treatment, the cell permeable fluorescent dye, dihydroethidium (DHE, Molecular Probes,
Eugene, OR) was used to determine the superoxide generation in the liver sections. DHE
can react with superoxide to form ethidium, which in turn intercalates with DNA and
produces nuclear ﬂuorescence(115). For DHE staining in frozen liver sections, cryosections
were incubated with 5 μM DHE for 30 min at 37°C in dark, washed with PBS and captured
at ×200 magnification (XI 71 Olympus, Tokyo, Japan).
Malondialdehyde (MDA) is the most frequently used biomarker of oxidative stress in
many health problems(116). MDA content test was performed to further confirm the ROS of
diabetic livers after FGF1 treatment. Briefly, 50μl liver tissue lysate was incubate with 8.1%
SDS, 20% Acetic acid and 0.57%TBA at 90℃ for 70 min. Then cold in ice and centrifuged
at 4000x g for 15 min. The fluorescence intensity of final MDA content in each sample
20

was detected by a microplate reader (SpectraMax M3; Molecular Devices, Sunnyvale, CA)
under specific wavelength conditions (OD=540μm). The final MDA content in each sample
was calculated as: MDA= (OD of Sample-OD of Standard) *178/pro-concentration
(mmol/mg).
RNA extraction, cDNA synthesis and quantitative RT-PCR
Total RNA was extracted from liver tissues with TRIzol reagent (Invitrogen, Carlsbad,
CA). After quantified using a Nanodrop ND-1000 spectrophotometer, 1µg total RNA was
used to synthesize first-strand complimentary DNA (cDNA) using reverse transcription kit
(Promega, WI) following the manufacturer’s instructions. Quantitative RT-PCR reactions
were performed in duplicate on an ABI Prism 7500HT (PE Applied Biosystems) and were
normalized to GAPDH. All TaqMan® assay-on-demand primers were from Thermo Fisher
Scientific Inc. (Grand Island, NY). Sequences were as follows: GAPDH, Mm99999915_g1;
PAI-1, Mm00436753_m1; TNFα, Mm00443259_g1; VCAM-1, Mm01320970_m1; ICAM1, Mm00516023_m1; SREBF1, Mm00550338_m1; FAS, Mm00662319_m1 and SCD-1,
Mm00772290_m1.

Western blot analysis
The liver tissues from db/db mice were collected and homogenized. Protein lysates
from liver tissues were separated using 8-12% SDS-PAGE and electro-transferred onto a
nitrocellulose membrane. The protein blots were probed with antibodies against HO-1,
phosphorylated AMPKα/AMPKα, phosphorylated ACC/ACC, and phosphorylated
SREBP-1 (Cell Signaling Technology, Danvers, MA), CAT, NQO-1, PGC-1α, CPT-1α, βactin, and GAPDH (Santa Cruz biotechnology, Dallas, TX), Nrf2, SREBP-1, FAS, SCD-1
and PPARα (Abcam, Cambridge, MA). The immunoreactive bands were then detected by
incubating with the secondary antibody (Santa Cruz Biotechnology, Dallas, TX)
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conjugated

with

horseradish

peroxidase

and

visualizing

using

enhanced

chemiluminescence (ECL) reagents (Bio-Rad, Hercules, CA). The amount of the proteins
was analyzed using Image Lab analysis software and normalized against their respective
loading controls.

Statistical analysis
Statistical analyses were performed using the statistical software package
GraphPad Prism version 6 (GraphPad Software Inc., San Diego, CA, USA). Data are
expressed as mean ± SEM. Statistical significance was evaluated using the unpaired twotailed Student t test or one-way analysis of variance. Differences were considered
significant at a P value <0.05.

RESULTS
FGF1△HBS prevents NAFLD in db/db mice
Consistent with the findings in our previous study(85), FGF1△HBS treatment at 0.5
mg/kg every other day for 2 months greatly lowered blood glucose levels (Fig. 2A), along
with significant improvement in insulin sensitivity (Fig. 2B, C) in db/db mice. FGF1 △HBS
treatment did not change body weight (Fig. 2D), but markedly lowered liver weight (Fig.
2E) and prevented liver injury reflected by decreased ALT (Fig. 2F) and AST activity (Fig.
2G). Furthermore, FGF1△HBS treatment significantly decreased hepatic TG content (Fig.
2H), showing improved hepatic lipid metabolism.
Histological examination using H&E staining and Oil Red O staining confirmed the
antisteatotic effect of FGF1△HBS (Fig. 3A). Hepatic steatosis is associated with hepatic
inflammation and oxidative stress. In addition to its potent antisteatotic action, FGF1△HBS
also suppressed hepatic inflammation and oxidative stress reflected by reduced mRNA
expression of hepatic inflammatory markers including TNFα, PAI-1, ICAM-1 and VCAM-1
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(Fig. 3B-E) and inhibited super oxide generation (Fig. 3F, G) and MDA production (Fig.
3H) in db/db mice.

Fig. 2 The effects of FGF1△HBS on blood glucose, insulin sensitivity and liver injury
in 2-month-old db/db mice. (A) The blood glucose over the course of 2 months treatment
of db/db mice with FGF1△HBS (0.5 mg/kg body weight, every other day). (B and C) The
Blood glucose levels in IPGTT and integrated area under the curve (AUC) for changes in
blood glucose levels. (D and E) The body weight and liver weight changes in db/db mice.
(F and G) Plasma levels of ALT and AST. (H) Triglyceride contents in livers. Quantitative
data are expressed as mean ± SEM, n=10-13. *P < 0.05 vs. db/db mice.
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Fig. 3 The preventive effects of FGF1△HBS on hepatic inflammation and oxidative
stress in 2-month-old db/db mice. (A) Representative images of H&E and Oil Red O
staining of liver sections (magnification: X200). (B-E) The hepatic mRNA levels of TNFα,
PAI-1, ICAM-1 and VCAM-1 in db/db mice. (F and G) Representative images of DHE
staining of liver frozen sections (magnification: X200) and quantitative analysis of
fluorescent intensity of DHE staining. (H) MDA contents in liver tissues. Quantitative data
are expressed as mean ± SEM, n=10-13. *P < 0.05 vs. db/db mice.

FGF1△HBS preserves hepatic antioxidant in db/db mice
To investigate the molecular basis of FGF1△HBS for hepatic antioxidative effects, we
observed the activation of Nrf2, an essential transcription factor in antioxidative
responses(117, 118), in FGF1△HBS treated and non-treated db/db mice. As expected, the
expression of nuclear Nrf2 in db/db mice was elevated significantly after FGF1△HBS
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treatment for 2 months (Fig. 4A, B). Furthermore, the expression of Nrf2-mediated antioxidative downstream genes catalase (CAT), NAD(P)H Quinone Oxidase 1 (NQO-1) and
Heme Oxygenase 1 (HO-1), were significantly higher in FGF1△HBS-treated db/db mice
than those in PBS-treated db/db mice (Fig4. A and C-E). These results indicate that
FGF1△HBS reduce the hepatic oxidative stress by activating Nrf2-mediated antioxidative
signaling pathways.

Fig. 4 FGF1△HBS activating Nrf2-mediated anti-oxidative signaling pathway in liver
of 2-month-old db/db mice. (A) Protein expressions of nuclear Nrf2 and its downstream
target genes catalase (CAT), heme oxygenase-1 (HO-1) and NAD(P)H dehydrogenase
(quinone 1) (NQO-1) were determined by Western blot. (B-E) The quantitative analysis of
nuclear-Nrf2 (n-Nrf2), CAT, NQO-1 and HO-1 in Western blot results by densitometry.
Quantitative data are expressed as mean ± SEM, n=10-13*P < 0.05 vs. db/db mice.
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FGF1△HBS promotes hepatic lipid metabolic signaling in T2D
To decipher how FGF1△HBS regulates hepatic lipid metabolism in T2D, the key lipid
metabolism related signaling was evaluated in this study. As the key factors in de novo
fatty acid synthesis, FAS, SCD-1 and SREBP-1 at mRNA levels in db/db mice were
markedly reduced after FGF1△HBS treatment (Fig. 5A), as well as their expression at
protein levels were inhibited as indicated by western-blot (Fig. 5B-E). In addition, CPT-1α,
PPARα and PGC-1α, which play major roles in regulating fatty acid oxidation(119), were
significantly increased in FGF1△HBS-treated db/db mice compared to the control db/db
mice (Fig. 5B and 5F-H).
Notably, FGF1△HBS-mediated lipid metabolic regulation was accompanied by a
significant up-regulation of AMPK phosphorylation in db/db mice (Fig. 5B and 5I). The
phosphorylation of ACC and SREBP-1, which are the downstream targets of AMPK, were
also obviously upregulated by FGF1△HBS treatment in db/db mice (Fig. 5B and 5J, K),
suggesting that FGF1△HBS regulation of hepatic lipid metabolism was associated with
AMPK signaling pathway.
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Fig. 5 FGF1△HBS regulating lipid metabolic signaling pathway in liver of 2-month-old
db/db mice. (A) The hepatic mRNA levels of SREBP-1, FAS and SCD-1 in db/db mice.
(B) Protein expressions of hepatic lipogenic genes (m/pro SREBP-1, FAS, SCD-1),
hepatic fatty acid oxidation (CPT-1α, PGC-1α and PPARα) and AMPK signaling pathway
(p-AMPK/AMPK, p-ACC and p-SREBP-1) related genes were determined by Western blot.
(C-K) The quantitative analysis of Western blot results by densitometry. Quantitative data
are expressed as mean ± SEM, n=10-13. *P < 0.05 vs. db/db mice.
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DISCUSSION
NAFLD is highly associated with T2D. Considering the interaction between T2D and
NAFLD, it is certain that NAFLD is an increased risk for the development of T2D, while
T2D result in the progression of NAFLD to NASH, even to the end-stage of liver disease(64,
. However, the therapeutic options for NAFLD with T2D are rather limited. In the

104)

present study, we demonstrated that FGF1△HBS, a novel variant of FGF1 uncoupled
mitogenic and metabolic functions, effectively prevented hepatic steatosis, inhibited the
oxidative stress via Nrf2-mediated signaling pathway and promoted the hepatic lipid
metabolism possibly attributed to stimulation of AMPK-mediated signaling pathway in T2D.
As a paracrine FGF, FGF1 is known to be mitogenic and involved in the regulation
of diverse pathophysiological processes. The recent discovery of metabolic roles for FGF1
in adaptive adipose remodeling, metabolic homeostasis and insulin sensitivity has
expanded the functions of this classically known mitogen(9, 20). The liver is the critical
metabolic organ strongly involved in the major metabolic dysfunction in diabetes.
Increasing studies suggested the role of FGF1 in managing the metabolic dysfunction in
diabetes (9, 20), and demonstrated anti-steatosis and anti-inflammation effects for FGF1
protection against NAFLD in diabetes(24, 75). In addition to its potent glucose lowering and
insulin sensitizing effects, FGF1 would be a promising agent for NAFLD therapy. However,
the mechanism of FGF1 protection against NAFLD remains largely unknown. In the
present study, FGF1△HBS was used to define how FGF1 protects against NAFLD in T2D.
We used 2-month-old db/db mice to determine the preventive effects of FGF1△HBS
on diabetes-induced fatty liver disease. We demonstrated that FGF1 protected the T2D
mice from hepatotoxicity by inducing the antioxidant capacity and promoting the lipid
metabolism in livers. Our results showed that FGF1△HBS significantly attenuated the
hyperglycemia and promoted the insulin sensitivity in this early-stage db/db mice (Fig. 2
A-C). Moreover, FGF1△HBS significantly prevented injury, ameliorated the pathologic
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abnormality and reduced the hepatic lipid accumulation and inflammation in db/db mice
(Fig.2D-H and Fig. 3A-E). These results further confirmed the blood glucose lowering
capability and hepatic protective effects of FGF1△HBS were similar as that FGF1WT showed
in our previous studies(75, 85).
Oxidative stress refers to various deleterious processes resulting from an imbalance
between the excessive formation of ROS and limited antioxidant defenses(89), which is a
major factor responsible for the dysfunction of diabetic livers(88). In the present study, the
db/db mouse models exhibited robust oxidative stress in liver, indicated by upregulated
superoxide generation and MDA production, all of which were greatly inhibited by
FGF1△HBS (Fig.3 F-H). Among the mechanism responsible for the oxidative stress, Nrf2mediated signaling pathway plays a critical role in antioxidative responses by upregulating
multiple antioxidant components(117,

.

118)

Our findings clearly demonstrated that Nrf2

activation was upregulated by FGF1△HBS in livers of T2D, as indicated by increased
nuclear translocation of Nrf2 and upregulation of Nrf2 downstream anti-oxidative genes,
CAT, NQO-1 and HO-1 (Fig. 4). These finding suggest that the anti-oxidative functions of
FGF1△HBS are linked to Nrf2 pathway.
Lipid metabolic disturbance is common in diabetic and NAFLD, which is
characterized by the excess fatty acid synthesis and impaired lipid catabolism(120, 121).
Activation of AMPK leads to the phosphorylation of key metabolic enzymes and
transcriptional regulators that are linked to cellular metabolism, such as glucose uptake,
fatty acid synthesis and oxidation(122). In addition to reduction of TG and lipid accumulation
in FGF1△HBS-treatment db/db mice, FGF1△HBS also downregulated the important
lipogenesis transcription gene, SREBP-1 and its downstream genes, FAS and SCD-1
(Fig.5A-E). Moreover, FGF1△HBS significantly upregulated the fatty acid oxidation related
genes, CPT-1α, PPARα and PGC-1α (Fig.5B and 5F-H). These findings indicate that
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FGF1△HBS protection against NAFLD is associated with AMPK-mediated lipogenesis
inhibition and fatty acid oxidation activation.
These data firstly indicate that the potent preventive effects of FGF1△HBS against
NAFLD in T2D were strongly associated with the Nrf2 mediated-anti-oxidative pathway
and AMPK mediated lipid metabolism pathway.
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CHAPTER II
THE ROLE OF NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2 IN
FIBROBLAST GROWTH FACTOR 1 PROTECTION AGAINST NON-ALCOHOLIC
FATTY LIVER DISEASE

INTRODUCTION
1. Oxidative stress in diabetes
Oxidative stress refers to increased cellular production of reactive oxygen (ROS)
and nitrogen (RNS) species and impaired clearance of such species by antioxidant
defense systems that cause damage to lipids, proteins and DNA(123). Numerous studies
have indicated that oxidative stress as a key regulator in chronic pathological status
including cancer, cardiovascular diseases, chronic inflammation, autoimmune disorders
and diabetes(124). In particular, increasing evidence has established the role of oxidative
stress in the development of diabetic complications including diabetic cardiomyopathy,
retinopathy, nephropathy, neuropathy, and microvascular disease(125). The causes of
increased oxidative stress in the diabetic complications are partially known by the
activation of transcription factors, advanced glycated end products (AGEs), and protein
kinase C(126, 127). In diabetes, the hyperglycemia increases the production of free radicals.
The excess free radicals and the imbalance of antioxidant defense mechanisms result to
the damaged cellular organelles and enzymes, increased lipid peroxidation, and insulin
resistance. These consequences of oxidative stress aggressive cause the damage of
diabetic complications(126). Meanwhile, oxidative stress has the strong cross-talk with the
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fibrosis, inflammation, cell death and metabolic stress, which accelerate the tissue
damage in diseases(128, 129). Therefore, antioxidant therapy has been attractive treatment
options for diabetes treatment.

2. Oxidative stress in NAFLD
NAFLD is characterized by excess fatty acid in hepatocytes because of the increased
inflow of free fatty acids and/or de novo lipogenesis, and decreased fatty acid oxidation
caused by initial metabolic disturbance. As the “the first hit”, this marked hepatic fat
accumulation is the risk for the development of NAFLD, which increases the susceptibility
of the liver to secondary damages(92). Excess lipids in the hepatocyte impairs the
mitochondria oxidation, inactivates the electron transport chain complexes and stimulates
peroxisomal and microsomal pathways of fat oxidation. The consequent generation of
ROS and reactive aldehydic derivatives causes oxidative stress and cell death, via
multiple factors such as ATP, nicotinamide adenine dinucleotide, glutathione depletion,
DNA, and lipid damage(89).

There has a vicious circle between the abnormal lipid

peroxidation and the excess ROS in NAFLD, which continually aggravates the oxidative
stress and abnormal metabolic regulation, further exacerbates the cell death in NAFLD.
As the critical “second hit” in NAFLD, oxidative stress also triggers production of
inflammatory cytokines, causing inflammation leading to the progression of steatohepatitis
and cirrhosis. This ultimately results in the progress of NAFLD and end-stage liver failure.
Application of antioxidants suggests a rational curative strategy to prevent the liver injury
from oxidative stress(88, 130).

3. The role of nuclear factor E2–related factor 2 in diseases
Nrf2 is a transcription factor that widely distributed in the liver, kidney, muscle, lung, heart
and other organs. Nrf2 is an important sensor in response to the toxic substances
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and oxidants in the body that is critical for cellular defense mechanisms. In non-stressed
cells, Nrf2 is inactive in the cytoplasm because of the repressive effect of kelch like ECH
associated protein 1 (Keap1). Once activated by ROS or electrophilic agents, Nrf2
translocate into the nucleus and binds to the promoters of a variety genes including the
genes relevant to anti-inflammation, anti-apoptosis and anti-aging(131). Nrf2 mainly binds
to antioxidant response element (ARE) to regulate its target genes, such as NAD(P)H
quinone oxidase 1 (NQO1), heme oxygenase 1 (HO1)(132, 133). The potential protective
roles of Nrf2-mediated antioxidant activation in diabetic complications, such as diabetic
nephropathy, cardiomyopathy and limb ischemia, have been widely studied (134-136).
Recently, Nrf2 pathway has been investigated as a potential target to metabolic
syndrome, such as obesity, insulin resistance and T2D(137,

. For example, the liver

138)

expression of Nrf2 and its downstream genes were decreased in high fat diet fed mice.
Nrf2 knockout mice have TG and ROS accumulation in liver(139). The Nrf2 activator, such
as sulforaphane, can activate Nrf2 to inhibit the hepatic oxidative stress and inflammation,
following with the protection against the hepatic lipid accumulation(140). Xue et al
demonstrated that adipocyte-specific ablation of Nrf2 in ob/ob mice resulted in reduced
antioxidant response, but increased plasma triglyceride and aggravated insulin
resistance(137, 141,

142)

. All these results demonstrate that in addition to the anti-oxidant

stress, Nrf2 is also involved in regulating insulin sensitivity and maintaining the glucose
and lipid homeostasis.
In the present study, we found that FGF1△HBS significantly ameliorated the hepatic
oxidative stress in db/db mice associated with the upregulation of nuclear Nrf2, and its
downstream target genes. Base on the previous studies, we hypothesize that Nrf2mediated signaling pathway might play a critical role in FGF1 protection against NAFLD
in T2D.
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MATERIALS AND METHODS
Cell treatment
The human hepatocellular carcinoma cell line (HepG2) was purchased from the
American Type Culture Collection. Palmitate (Pal) provided by Sigma-Aldrich (St. Louis,
MO, USA) was used to mimic diabetes-induced hepatic lipid toxicity including oxidative
damage and lipid metabolism disorder seen in db/db mice. HepG2 cells were cultured in
DMEM containing 5.5 mM D-glucose, 10% fetal bovine serum, 100 units/ml penicillin, and
100 μg/ml streptomycin, and incubated in a humidified atmosphere of 5% CO2 at 37 °C
and passaged every 2 days by trypsinization. After serum starvation for 24 hours, HepG2
cells and Nrf2 knockdown-HepG2 cells were treated with 100 μM Pal or control
with/without insulin in serum free medium for 12 hours, followed by incubation with FGF1WT
and FGF1△HBS for additional 12 hours, respectively. Cells were collected for the following
experiments.

All cell culture experiments were carried out under the guidelines of

biosafety and approved by the Biosafety Committee of the University of Louisville.

Palmitate preparation
Pal was dissolved in 50% ethanol solution at 60 °C, and further dissolved in 2% fatty
acid-free bovine serum albumin (BSA) to make 10 mM Pal stock solution, then filtered and
stored at -20 °C.

Oil-Red O analysis for cells
Cells were seeded in 6-well plate at a density of 104 cells per well. After stimulated
with Pal in the presence of insulin for 12 hours, followed by incubation with or without
FGF1WT and FGF1△HBS for additional 12 hours, cells were washed with PBS for three times,
and then fixed in 4% paraformaldehyde for 20 mins. After washing with PBS three times,
cells were stained with 0.5% Oil Red O for 10 mins at room temperature. Then the
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additional Oil Red O was removed by washing with PBS. To quantify Oil Red O content,
isopropanol (1ml) was added into each well, shaking the plate for 10 mins at room
temperature. The intensity of Oil Red O content in each sample was detected by a
microplate reader under specific wavelength conditions (OD=520nm).

Quantitative determination of oxidative stress
HepG2 cells were cultured and treated as described above, then incubated with 5
μM DHE in HBSS medium for 30 minutes at 37°C. Nuclear DHE positive staining indicates
superoxide generation in cells. The ﬂuorescence intensity was detected using a microplate
reader (SpectraMax M3; Molecular Devices, Sunnyvale, CA) under specific wavelength
conditions (excitation, 518 nm; ﬂuorescence, 605 nm).
For MDA analysis in vitro, 50μl proteins from cells were incubate with 8.1% SDS,
20% Acetic acid and 0.57%TBA at 90℃ for 70 mins. Then centrifuged at 4000x g for 15
mins. The calculation of the fluorescence intensity finally MDA content in each sample
was same as that performed in vivo.

SiRNA transfection
knockdown of Nrf2 was performed using small interfering RNAs (siRNAs) targeting
Nrf2 and control siRNA (Santa Cruz Biotechnology, CA) according to the manufacturer’s
protocol. HepG2 cells were seeded at a density of 20 X 104 cells/well in 6-well plates and
were transfected with Nrf2-siRNA using lipofectamine 2000 reagent (Invitrogen) at a final
concentration of 100 nmol/L in Opti-MEM (GIBCO BRL) for 6 hours, respectively. Then
cells were cultured with normal medium for additional 16 hours to determine the
knockdown efficiency.
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Triglyceride content determination in cells
Cells were seeded in 6-well plate at a density of 20X104 per well. After stimulated
with Pal and treated with FGF1WT and FGF1△HBS in the present of insulin, cells were
washed with PBS for three times and then incubated with 0.3 ml, 0.25M NaOH for 10 mins.
Cells were scraped into the tube and incubated with hexane/isopropanol mixture (3:1) for
1 hour, then centrifuged at 10000g for 5 mins and then transferred the supernatants to a
new tube. The supernatant was evaporated at room temperature overnight. A TG kit
(Thermo Scientific, Waltham, MA) was used to solubilize the lipid pellet. After incubation
with TG buffer for 10 mins at 37℃, the levels of TG content in each well was detected by
a microplate reader under specific wavelength conditions (OD=505 nm).

Western blot analysis
The above cultured HepG2 cells were collected and lysed. Lysate proteins from liver
tissues and cells were separated using 8-12% SDS-PAGE and electro-transferred onto a
nitrocellulose membrane.

Statistical analysis
Statistical analyses were performed using the statistical software package,
GraphPad Prism version 6, (GraphPad Software Inc., San Diego, CA, USA). Data are
expressed as mean ± SEM. Statistical significance was evaluated using the unpaired twotailed Student t test or one-way analysis of variance. Differences were considered
significant at a P value <0.05.
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RESULTS
FGF1 prevents Pal-induced oxidative stress in an insulin-dependent manner in
HepG2 cells
As shown in DHE staining result, the hepatic superoxide production was higher in
Pal-induced HepG2 cells compared to the Control. The ROS accumulation in Pal-induced
HepG2 cells was not decreased by FGF1WTor FGF1△HBS (FGF1) treatment alone, but
obviously inhibited by FGF1 treatment in the present of insulin (Fig. 6A). In agreement
with DHE result, FGF1 effectively inhibited the oxidative stress in an insulin dependent
manner in Pal-induced HepG2 indicated by MDA analysis (Fig. 6B, C). Compared to the
control, Pal significantly suppressed the expression of nuclear Nrf2 in HepG2 cells.
Treatment with FGF1 significantly preserved Pal-induced reduction of nuclear Nrf2 in
HepG2 cells. The marked upregulation of nuclear Nrf2 was shown in Pal-induced HepG2
cells after FGF1 treatment with insulin, which was accompanied by a significant increase
in expression of its downstream anti-oxidative genes, CAT, HO-1 and NQO-1 (Fig. 7).
These results suggest that FGF1 prevents Pal-induced hepatic oxidative stress possibly
by restoring the antioxidant capability via Nrf2-mediated signaling.

37

Fig. 6 FGF1 preventing from Pal-induced hepatic oxidative stress in HepG2 cells.
(A and B) Representative images (magnification: X100) and quantitative analysis of
fluorescent intensity of DHE staining in Pal-induced HepG2 cells. (C) MDA content.
Quantitative data are expressed as mean ± SEM, n=3-5. #P<0.05 vs. Ctrl; *P < 0.05 vs.
Pal; &P < 0.05 vs. Pal+Ins; $P < 0.05 vs. Pal+FGF1△HBS or Pal+FGF1WT.
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Fig. 7 FGF1 preventing from Pal-induced hepatic oxidative stress via activating
Nrf2-mediated anti-oxidative signaling pathway in HepG2 cells. (A) The protein
expressions of nuclear Nrf2 and Nrf2 target genes CAT, HO-1 and NQO-1 in HepG2 cells
were determined by Western blot. (B-E) The quantitative analysis of Western blot results
by densitometry. Quantitative data are expressed as mean ± SEM, n=3-5. #P<0.05 vs. Ctrl;
*P < 0.05 vs. Pal; &P < 0.05 vs. Pal+Ins; $P < 0.05 vs. Pal+FGF1△HBS or Pal+FGF1WT.

FGF1 prevents Pal-induced lipotoxicity in an insulin-dependent manner in HepG2
cells
Pal treatment caused a clear increase of TG accumulation in HepG2 cells
compared with the Control (Fig. 8A). Furthermore, both FGF1△HBS and FGF1WT treatment
prevented Pal-induced lipid accumulation in HepG2 cells in an insulin-dependent manner,
reflected by intracellular TG content analysis and Oil-Red O staining (Fig. 8A and 8B). In
the presence of insulin, FGF1 dramatically decreased the expression of m/proSREBP-1,
FAS and SCD-1 (Fig. 9A-D) and increased the expression of CPT-1α, PGC1α and PPARα
(Fig. 9A, E-G). In addition, the dramatic reduction of phosphorylated AMPK by Pal in
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HepG2 cells was preserved by FGF1 treatment, along with the increased phosphorylation
of its downstream genes ACC and SREBP-1 (Fig. 9A, H-J).

Fig. 8 FGF1 preventing from Pal-induced hepatic lipotoxicity in HepG2 cells. (A)
Triglyceride contents. (B) Representative images of Oil Red O staining and Oil Red O
content analysis. Quantitative data are expressed as mean ± SEM, n=3-5. #P <0.05 vs.
Ctrl; *P < 0.05 vs. Pal; &P < 0.05 vs. Pal+Ins; $P < 0.05 vs. Pal+FGF1△HBS or Pal+FGF1WT.
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Fig. 9 FGF1 inhibiting lipogenesis and promoting lipid oxidation signaling in PalHepG2 cells. (A) Protein expressions of lipogenic genes (m/pro SREBP-1, FAS, SCD-1),
fatty acid oxidation (CPT-1α, PGC-1α and PPARα) and AMPK signaling pathway (pAMPK/AMPK, p-ACC/ACC and p-SREBP-1) in HepG2 cells were detected by Western
blot. (B-J) The quantitative analysis of Western blot results by densitometry. Quantitative
data are expressed as mean ± SEM, n=3-5. #P <0.05 vs. Ctrl; *P < 0.05 vs. Pal; &P < 0.05
vs. Pal+Ins; $P < 0.05 vs. Pal+FGF1△HBS or Pal+FGF1WT.
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Nrf2 silencing abolishes the protective effects of FGF1 against oxidative stress
but not lipotoxicity
In addition to playing a central role in responding to oxidative stress, Nrf2is also a
target for regulating lipid metabolism(143). Nrf2 knockdown significantly aggravated the
oxidative damage compared to Control-siRNA group, neither FGF1△HBS nor FGF1WT
decreased the MDA content after Nrf2 knockdown in HepG2 cells (Fig. 10A). Moreover,
FGF1 did not affect the protein levels of nuclear Nrf2, HO-1, CAT and NQO-1 in Palinduced HepG2 cells transfected with Nrf2-siRNA compared to Control-siRNA group
(Fig. 10B-G), suggesting Nrf2 silencing abolished the preventive effects of FGF1 from
Pal-induced oxidative damage. However, Nrf2 knockdown did not affect FGF1
prevention from TG accumulation in Pal-induced HepG2 cells (Fig. 11A). Meanwhile,
FGF1 inhibiting Pal-induced upregulation of m/pro-SREBP-1, FAS, and SCD-1 also was
not affected by Nrf2 knockdown in cells (Fig. 11B-E). Taken together, our results indicate
that Nrf2 is not required for the inhibitory effects of FGF1 on Pal-induced lipid disorder in
HepG2 cells.
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Fig. 10 Knockdown of Nrf2 in the HepG2 cells attenuated the beneficial effects of
FGF1 on Pal-induced oxidative stress in HepG2 cells. (A) MDA contents in Pal-induced
HepG2 cells. (B) The expressions of nuclear Nrf2, total Nrf2 (t-Nrf2), HO-1, CAT and NQO1 were determined by Western blot. (C-G) The quantitative analysis of nuclear Nrf2, t-Nrf2
and HO-1 western blot results by densitometry. Quantitative data are expressed as mean
± SEM, n=3-5. #P <0.05 vs. Control-Control-SiRNA; *P < 0.05 vs. Pal-Control-SiRNA; &P
< 0.05 vs. Control-Nrf2-SiRNA; $P < 0.05 vs. Pal-Nrf2-SiRNA.
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Fig. 11 Knockdown of Nrf2 cells affect the beneficial effects of FGF1 on Pal-induced
lipiotoxicity in HepG2 cells. (A) TG content in HepG2 cells. (B) Protein expressions of
lipogenic genes (m/pro SREBP-1, FAS, SCD-1) were determined by Western blot. (C-E)
The quantitative analysis of m/pro SREBP-1, FAS, SCD-1 Western blot results by
densitometry. Quantitative data are expressed as mean ± SEM, n=3-5. #P <0.05 vs.
Control-Control-SiRNA; *P < 0.05 vs. Pal-Control-SiRNA; &P < 0.05 vs. Control-Nrf2SiRNA; $P < 0.05 vs. Pal-Nrf2-SiRNA.

DISSISION
Among the many potential pathogenic mechanisms responsible for the progression
of NAFLD, oxidative stress is recognized as a secondary hit driving the pathogenesis of
NAFLD. Oxidative stress exacerbates hepatic inflammation and fibrosis, leading to further
disruption of hepatic lipid metabolism(87-92). It suggests a close relationship between
dysregulated lipid homeostasis and oxidative stress in the pathogenesis of NAFLD(142, 143).
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In the intracellular signaling system that regulates oxidative stress responses, Nrf2
is a well-known master regulator of the cellular adaptive response to oxidative damage(137).
Emerging evidence indicated that, in addition to regulating hepatic antioxidant defenses,
Nrf2 plays a critical role in regulating the hepatic energy metabolism pathways(137, 141, 144).
To further understand the protective effects of FGF1 against lipotoxicity in hepatocytes,
Pal was used to mimic T2D-induced lipotoxicity to explore the protective mechanism of
FGF1(145, 146).
Pal-induced HepG2 cells successfully mimicked the phenotype of diabetes-induced
oxidative stress and lipid toxicity. Both FGF1△HBS and FGF1WT protected Pal-induced
HepG2 cells against hepatic lipotoxicity in an insulin dependent manner (Fig.6 and Fig.8),
following with a significant increase in Nrf2 signaling and AMPK signaling (Fig. 7 and Fig.
9). These results further confirmed the protection of FGF1 against NAFLD was associated
with Nrf2- and AMPK-mediated signaling pathways.
Accordingly, we detected the role of Nrf2 for FGF1 treatment in NAFLD. As expected,
FGF1 could not reverse Pal-induced ROS accumulation after Nrf2 silencing in HepG2 cells
after Nrf2 knockdown (Fig. 10). This result suggests that Nrf2 play a critical role in the antioxidative stress action of FGF1 in hepatic cells. However, FGF1 administration still
attenuated lipid accumulation and lipogenesis genes expression in Pal-induced HepG2
cells with Nrf2 knockdown (Fig. 11). These results suggest that Nrf2 silencing was not
required for FGF1 protection against Pal-induced lipid disorder.
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CHAPTER III
THE ROLE OF AMP-ACTIVATED PROTEIN KINASE α IN FIBROBLAST GROWTH
FACTOR 1 PROTECTION AGAINST NON-ALCOHOLIC FATTY LIVER DISEASE

INREODUCTION
1. Lipid metabolism in liver
Lipid metabolism is a process of lipid synthesis and degradation in cells. The liver is
a central metabolic organ in the regulation of glucose and lipid metabolism. Lipid
metabolism in hepatocytes can be summarized by three processes: (1) lipid absorption,
including lipids and fatty acids uptake and fatty acid synthesis (de novo lipogenesis); (2)
lipid storage, including triglyceride synthesis and lipid droplets formation; and (3) lipid
catabolism, including lipolysis, β-oxidation, and the very low-density lipoproteins (VLDL)
secretion(120,

. Lipid metabolic disorders are characterized by a change in the

121)

concentration and/or composition of lipoproteins in the blood, such as low-density
lipoprotein (LDL), cholesterol, VLDL, and TG(147).

2. Lipid metabolic dysregulation in diabetes and NAFLD
Lipid metabolic dysregulation is common in diabetic and NAFLD patients. Insulin
deficiency, insulin resistance, obesity, and genetic factors are related the lipoprotein
production and catabolism. T2D has an increased prevalence of lipid abnormalities. T2D
patients usually show decreased HDL level and elevated VLD. LDL levels is usually not
significantly different in T2D patients compared with nondiabetic individuals (148). The liver
plays a particularly important role in lipid metabolism that involves in the lipoprotein
46

synthesis, lipid transport and is the main site for fatty acid oxidation and ketone body
formation. NAFLD is characterized by excessive fat accumulation in the liver, showed by
the increased flux of free fatty acids (FFA), lipoprotein lipase (LPL) and TG
accumulation(149).
Generally, the mechanism contributing to the pathogenesis of NAFLD includes the
extrahepatic mechanisms and intrahepatic mechanisms. The extrahepatic mechanism
includes the adipose tissue that increases FFA transporting to the liver and many dietary
macro- and micro-nutrients, such as saturated fatty acids, polyunsaturated fatty acids (n3PUFAs), and carbohydrate protein, participating in the increased de novo fatty acid
synthesis. While some key enzymes, such as acetyl-CoA carboxylase (ACC), fatty acid
synthase (FAS), stearoyl-CoA desaturase-1 (SCD-1) and diacylglycerol acyltransferase2 (DGAT-2), and some key transcription factors, such as sterol regulatory element-binding
protein 1 (SREBP-1), insulin induced gene-1 (Insig-1) and carbohydrate-responsive
element-binding protein (ChREBP), play important roles in de novo lipogenesis as the
intrahepatic mechanisms in NAFLD(66). The excessive fat depositions in the liver not only
due to increased fatty acid synthesis, but also affected by the decreased mitochondrial βoxidation, decreased clearance of VLDL or these factors in combination(150). Studies
showed that hepatic fat from the de novo pathway is less than 5% under basal conditions,
however, up to 30% of fat deposited from de novo lipogenesis in the liver under
pathological conditions(66, 151).
In addition, lipid metabolic disturbance in liver is also associated with the
Inflammation, oxidative stress, fibrosis and ER stress(152), increasing the complexity of the
molecular and pathological mechanism of liver. It is still difficult to understand the lipid
metabolism in the development of NAFLD. The common management of lipid disorder in
diabetes and NAFLD is directed at improving glycemic control, altering dietary composition,
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and reducing calories intake(153). Hence, study on drug development for lipid metabolic
regulation in liver is of great importance to the prevention and treatment of NAFLD.

3. The role of AMP-activated protein kinase (AMPK) in diseases
The AMP-activated protein kinase (AMPK) is a ubiquitously expressed
serine/threonine protein kinase that is well-known as a central regulator of multiple
metabolic pathways and may have therapeutic importance for treating obesity, insulin
resistance, T2D, NAFLD, and cardiovascular disease. AMPK plays a critical role in
increasing glucose uptake, fatty acid oxidation (FAO), mitochondrial biogenesis, and
autophagy, and suppressing the synthesis of fatty acids, cholesterol, via regulating
metabolic related proteins(154-156). AMPK is a heterotrimeric complex composed of catalytic
α-subunit (α1, α2) and regulatory β- (β1, β2) and γ-subunits (γ1, γ2, γ3) with multiple
isoforms for each subunit. These subunits are encoded by distinct genes and have unique
tissue specific expression profiles(122, 157). Compelling evidences indicate that AMPK plays
an essential role in the development of NAFLD. Liver specific overexpression of AMPK α1
in T2D protected against the steatosis reflected by reduction of lipogenic gene expression
and TG content(158). Overexpression of AMPK α1 in hepatocytes not only increased the
fatty acid clearance via mitochondrial FAO as indicated by CPT-1 expression, but also
decreased

TG

accumulation(159).

Liver-specific

knockout

of

AMPKα2

showed

hyperglycemia and elevated hepatic glucose production compared to controls(160).
Mechanistically, AMPK promotes the lipid metabolism in liver via regulating the important
enzymes and transcription factors of lipid biosynthesis and FAO, such as FAS, ACC,
SREBP-1 and SREBP-2(155, 161). AMPK also regulates some mediators for the control of
total mitochondrial content, quality, and function, such as PPAR-γ1 coactivator (PGC-1α)
and histone deacetylases (HDAC) and the unc-51-like autophagy activating kinase
1(ULK1)(162). In addition to altering metabolic pathways, AMPK also triggers key proteins
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in controlling inflammatory cell proliferation, ER stress and oxidative stress pathways,
including NF-kB, mTOR, and Nrf2 activity(133, 163, 164). Therefore, AMPK would be a critical
therapeutic target for NAFLD.
The relationship between AMPK and Nrf2-mediated metabolic regulation has been
investigated for many years. Many recent studies found that Nrf2 and AMPK interacted
to regulate each other under different pathological and physiological conditions. For
example, Mo et al showed that berberine activated the AMPK and Nrf2 pathway against
inflammation in both lipopolysaccharide-shocked macrophages and mice, in which AMPK
worked at the upstream of Nrf2(165). However, Sids et al demonstrated that Nrf2 was
independent of AMPK signaling pathways in human hepatocarcinoma cells treated with
AMPK activator AICAR(117). In Yang’s study, alpha-lipoic acid improved high-fat dietinduced

hepatic

steatosis

by

modulating

Nrf2-mediated

antioxidation

and

SIRT1/LKB1/AMPK pathway-mediated lipid metabolism(87). Thus, the interaction of Nrf2
and AMPK has not been clearly clarified, especially after stimulation by FGF1.
In this study, our results showed that FGF1 prevented NAFLD along with
upregulation of Nrf2- and AMPK-mediated signaling pathways. However, Nrf2 silencing
only abolished FGF1 protection against Pal-induced hepatic oxidative stress. Thus, we
hypothesized that AMPK-mediated signaling pathway would be critical for FGF1 protection
against NAFLD in T2D.

MATERIALS AND METHODS
Primary mouse hepatocyte isolation and culture
Primary mouse hepatocytes were isolated using a method described previously(166).
Briefly, Hepatocytes were isolated from C57/BL6J mice by in situ digestion under aseptic
conditions. The liver was perfused with ethylene glycol-bis(2-aminoethylether)-N,N,N',N'tetraacetic acid (EGTA) solution (10 mM HEPES, 5 mM glucose, 138 mM NaCl, 5.4 mM
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KCl, 28.3 mM NaHCO3, 0.12 mM Na2HPO4, 0.56 mM NaH2PO4 and 0.5 mM EGTA , pH
7.4) and collagenase solution (10 mM HEPES, 138 mM NaCl, 5.4 mM KCl, 28.3 mM
NaHCO3, 0.12 mM Na2HPO4, 0.56 mM NaH2PO4, containing 0.0857 U/ml collagenase
D (Roche Diagnostics, Indianapolis, IN) and 3.8 mM CaCl2, pH 7.4). The isolated
hepatocytes were washed with HBSS (Gibco BRL, Life Technologies, Inc., NY) and then
were cultured at a density of 20 × 104 cells/dish after the cell viability was assessed by the
trypan blue exclusion test. Primary mouse hepatocyte was cultured in Waymouths
medium supplemented with 5% (w/v) fetal bovine serum (FBS) (Gibco BRL, Life
Technologies, Inc.), antibiotic-antimycotic (Gibco 100 units/mL of penicillin, 100μg/mL of
streptomycin, 0.25μg/mL of Fungizone) and ITS supplement (VWR).
After AMPKα1/2-siRNA transfection, primary mouse hepatocytes were induced by
100 μM Pal with or without FGF1WT and FGF1△HBS treatment for 12 hours as described in
HepG2 cells. Then cells were collected to observe the oxidative stress and lipid
metabolism after FGF1WT and FGF1△HBS administration when AMPK silencing.

AMPKα1/2-siRNA transfection
Knockdown of AMPKα1/2 was performed using small interfering RNAs (siRNAs)
targeting AMPKα1/2 (Santa Cruz Biotechnology, CA) according to the manufacturer’s
protocol. The scramble siRNA sequences were used as control. HepG2 cells or primary
hepatocytes were seeded at a density of 20X104 cells/well in 6-well plates were
transfected with AMPKα1/2-siRNA using lipofectamine 2000 reagent (Invitrogen) at a final
concentration of 100 nmol/L in Opti-MEM (GIBCO BRL) for 6 hours, respectively. Then,
cells were cultured in normal medium for additional 16 hours to determine the knockdown
efficiency.
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Statistical analysis
Statistical analyses were performed using the statistical software package,
GraphPad Prism version 6, (GraphPad Software Inc., San Diego, CA, USA). Data are
expressed as mean ± SEM. Statistical significance was evaluated using the unpaired twotailed Student t test or one-way analysis of variance. Differences were considered
significant at a P value <0.05.

RESULTS
AMPK silencing abolished the protective effects of FGF1 against Pal-induced
oxidative stress and lipid disorder in primary hepatocytes
To detect the role of AMPK in FGF1-mediated inhibiting effects on hepatic
lipotoxicity, AMPK knockdown was performed using specific siRNA against AMPKα in
mouse primary hepatocyte. Compared to control-siRNA, AMPKα-siRNA-mediated
knockdown of AMPKα remarkably reduced AMPK expression (Fig. 12B,C) and
phosphorylation (Fig. 12B,D), which was accompanied by downregulation of its
downstream target genes ACC (Fig. 12B,F) and SREBP-1 (Fig. 12B,E) phosphorylation.
Furthermore, knockdown AMPKα dramatically aggravated Pal-induced lipid
accumulation, reflected by increased TG content compared with control-siRNA treatment
(Fig. 12A), and completely abolished the preventive effects of both FGF1△HBS and
FGF1WT against lipid accumulation (Fig. 12A) and lipogenic genes upregulation (Fig.
12B,H-J), and FAO gene downregulation. More importantly, knockdown AMPKα also
aggravated Pal-induced oxidative stress, reflected by MDA production compared with
control-siRNA treatment (Fig. 13A), and completely abolished the preventive effects of
both FGF1△HBS and FGF1WT against oxidative stress-induced by Pal in primary
hepatocytes (Fig. 13A). This was accompanied by almost complete attenuation of Nrf2
nuclear translocation (Fig. 13B,C) and its downstream genes expression (Fig. 13B,D-F)
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under basal and both FGF1△HBS and FGF1WT stimulated conditions, but without
significant effects on total Nrf2 (Fig. 13B,D) and CAT (Fig. 13B,G) expression. These
results support the notion that AMPK plays a central role in FGF1 preventing from Palinduced hepatic lipid metabolic disorder and oxidative stress.
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Fig. 12 AMPK silencing abolished the protective effects of FGF1 against PalInduced lipotoxicity in primary mouse hepatocyte. (A) Triglyceride contents. (B) Protein
expressions of AMPK signaling pathway (p-AMPK/AMPK, p-ACC and p-SREBP-1),
PPARα and lipogenic genes (m/pro SREBP-1, FAS, SCD-1) in primary mouse hepatocyte.
(C-J) The quantitative analysis of Western blot by densitometry. Quantitative data are
expressed as mean ± SEM, n=3-5. #P <0.05 vs. Control-Control-SiRNA; *P < 0.05 vs. PalControl-SiRNA; &P < 0.05 vs. FGF1WT-Control-SiRNA; $P < 0.05 vs. FGF1△HBS -ControlSiRNA.

Fig. 13 AMPK silencing abolished the protective effects of FGF1 against PalInduced oxidative stress in primary mouse hepatocyte. (A) MDA contents in primary
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hepatocyte. (B) Protein expressions of Nrf2-mediated anti-oxidative stress signaling
pathway (n-Nrf2, t-Nrf2, HO-1, NQO-1 and CAT) in primary mouse hepatocyte. (C-G) The
quantitative analysis of n-Nrf2, t-Nrf2, HO-1, NQO-1 and CAT Western blot results by
densitometry. Quantitative data are expressed as mean ± SEM, n=3-5. #P <0.05 vs.
Control-Control-SiRNA; *P < 0.05 vs. Pal-Control-SiRNA; &P < 0.05 vs. FGF1WT-ControlSiRNA; $P < 0.05 vs. FGF1△HBS -Control-SiRNA.

DISSISION
AMPK is a central metabolic regulator of lipid and glucose metabolic homeostasis
in many metabolic diseases. Activation of AMPK leading to the phosphorylation of key
metabolic substrates and transcriptional regulators plays a critical role in fatty acids
synthesis, glucose uptake, FAO and mitochondrial biogenesis. In addition, AMPK also
involves in the regulation of the inflammation, oxidative stress and apoptosis through direct
phosphorylation of multiple targets(122, 154, 167).
The results in Chapter III indicated that knockdown of Nrf2 abolished the antioxidative stress effects of FGF1 but did not affect the inhibition on lipid accumulation and
upregulation on AMPK-signaling pathway of FGF1 in hepatic cells. In this study, we further
demonstrated that knockdown of AMPKα abolished not only FGF1 protection against Palinduced oxidative stress and Nrf2-mediated antioxidative signaling pathway, but also
FGF1 protection against Pal-induced lipid disorder and lipid metabolic signal dysregulation
(Fig.12A and 13A).
Collectively, these findings suggest that AMPK is required for FGF1 protection
against Pal-induced lipid metabolic dysregulation and oxidative stress in hepatic cells.
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CHAPTER IV
THE THERAPTUTIC EFFECTS OF A NOVEL FIBROBLAST GROWTH FACTOR 1
VARIANT ON NON-ALCOHOLIC FATTY LIVER DISEASE IN TYPE 2 DIABETES

INTRODUCTION
With the increasing incidence of obesity and T2D in every age group, the global
prevalence of NAFLD varies from 20-30%(168). A report from the Mayo Clinic pointed out
that people in their age of 40s and 50s show the highest incidence of either NAFLD or
T2D, which can be mainly explained by the delayed diagnosis(168). In NAFLD, most people
have no symptoms until they come to the medical attention. The progression of NAFLD
can be prevented in patients at the early stage with symptoms of enlarged liver, fatigue
and pain in the abdomen. Without the timely intervention, inflammation and scarring of the
liver can occur over time. The advanced symptoms that are not easy to be cured include
the abdominal swelling, enlarged blood vessels and spleen, yellow skin and eyes(169). In
T2D, the signs and symptoms often develop slowly. People can have T2D and not know
it for years until an acute medical condition occurs because of the unawareness of the
diabetic symptoms including the increased thirst and hunger, weight loss, fatigue and
blurred vision(170-174). Patients may take attention to T2D management only when the
complications appear.
All aged diabetic patients have a high burden of comorbidities, and more susceptible
to complications, as well as patients with NAFLD. T2D is associated with chronic
complications throughout the body and with significantly accelerated rates of several
microvascular complications such as nephropathy, retinopathy, and neuropathy, and
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atherosclerosis, leading to the physical disability, cognitive impairment and malnutrition
. NAFLD progresses to NASH in about 20% of cases, of which 20–25% may

(175, 176)

progress on to hepatic fibrosis and cirrhosis(93). A small proportion of individuals develop
advanced fibrosis, cirrhosis can lead to fluid buildup in the abdomen, veins swelling,
drowsiness and worsen to hepatic encephalopathy, even end stage liver disease,
hepatocellular carcinoma (HCC)(177). All these complications contribute to the excess
morbidity and mortality in aged individuals with NAFLD and diabetes.
Therefore, clinically, it is urgent and important to pay more attention to discover
therapeutic drugs. To ensure greater clinical relevance, we thus choose the aged db/db
model to determine the therapeutic effects of FGF1△HBS against NAFDL in T2D.

MATERIALS AND METHODS
Animal model
Late-stage 9-month-old male db/db mice were administered with FGF1△HBS or PBS
via intraperitoneal injection (0.5 mg/kg) every other day for 3 months. At the indicated timepoints, the blood glucose levels were determined by FreeStyle complete blood glucose
monitor (Abbott Diabetes Care Inc., Alameda, CA). All mice were housed under a 12:12h light/dark cycle at controlled temperature. All experimental procedures were approved
by the Institutional Animal Care and Use Committee of the University of Louisville. All the
other experiments were performed following the same protocol as described in CHAPTER
I.

RESULTS
Therapeutic Effects of FGF1△HBS on NAFLD in aged db/db mice
To explore the clinic translational potential, we further investigate whether
FGF1△HBS is sufficient to reverse the exacerbated liver injury in late-stage db/db T2D
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mice. We treated 9-month-old db/db mice with FGF1△HBS (0.5 mg/kg body weight) every
other day for 3 months. Pharmacological administration of FGF1△HBS almost completely
normalized the blood glucose levels (Fig. 14A) and significantly improved insulin
sensitivity (Fig. 14B, C). FGF1△HBS treatment slightly reduced body weight (data not
shown), but markedly reduced liver seizes and weight (Fig. 15A, B) and reversed liver
steatosis (Fig. 15C) and lipid accumulation (Fig. 15D). Furthermore, FGF1△HBS treatment
also prevented liver injury (Fig. 15E, F) and suppressed hepatic inflammation (Fig. 15GJ) and oxidative stress (Fig. 16A).
To validate the universal mechanism of the efficacy of FGF1△HBS on NAFLD, the
hepatic antioxidative and lipid metabolic markers were also examined. Likewise,
FGF1△HBS treatment markedly increased Nrf2 nuclear translocation (Fig. 16B, C) and
upregulated the expression of its downstream target genes (Fig. 16B, D-F). Furthermore,
FGF1△HBS treatment significantly suppressed the activation of SREBP-1 (Fig. 17A, B)
and the expression of its downstream target genes FAS, SCD-1 (Fig. 17C, D). In
addition, FGF1△HBS treatment increased expression of CPT-1α, PPARα, and PGC-1α
(Fig. 17A, E-G), which were accompanied by significant upregulation of AMPK (Fig. 17A,
H) and ACC (Fig. 17A, I) and SREBP-1 (Fig. 17A, J). These results suggest that
FGF1ΔHBS reverses NAFLD in late-stage T2D through the similar molecular pathways as
seen in early-stage T2D.

57

Fig. 14 The effects of FGF1△HBS on blood glucose and insulin sensitivity in 9-monthold db/db mice. (A) The blood glucose over the course of 3 months treatment of db/db
mice with FGF1△HBS (0.5 mg/kg body weight, every other day). (B and C) The Blood
glucose levels in IPGTT and integrated area under the curve (AUC) for changes in blood
glucose levels. Quantitative data are expressed as mean ± SEM, n=5-10. *P < 0.05 vs.
db/db mice.
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Fig.15 The therapeutic effects of FGF1△HBS on chronic NAFLD in 9-month old db/db
mice. 9-month old db/db mice treated with FGF1△HBS (0.5 mg/kg, every other day) for 3
months. (A and B) The liver size and weight. (C) Representative images of H&E-staining
and Oil Red O staining of liver sections (magnification: X100). (D) Hepatic TG content in
db/db mice. (E and F) The serum ALT and AST. (G-J) Analysis for mRNA levels of hepatic
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inflammatory marker (TNFα, PAI-1, ICAM-1 and VCAM-1).

Quantitative data are

expressed as mean ± SEM, n=5-10. *P < 0.05 vs. db/db mice.

Fig.16 FGF1△HBS reversed hepatic oxidative stress in 9-month old db/db mice. (A)
The hepatic TG content in db/db mice. (B) FGF1△HBS stimulated the Nrf2-mediated antioxidative stress signaling genes in on chronic NAFLD in db/db mice. The protein
expressions of n-Nrf2, CAT, HO-1 and NQO-1 were determined by Western blot. (C-F) The
quantitative analysis of n-Nrf2, CAT, HO-1 and NQO-1 Western blot results by
densitometry. Quantitative data are expressed as mean ± SEM, n=5-10. *P < 0.05 vs.
db/db mice.
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Fig.17 FGF1△HBS activated hepatic AMPK signaling pathway in 9-month old db/db
mice. (A) The expressions of AMPK signaling pathway related proteins (SREBP-1, FAS
and SCD-1, CPT-1α, PGC-1α, PPARα, p-AMPK/AMPK, p-ACC and p-SREBP-1) were
detected by Western blot. (B-J) The quantitative analysis of Western blot results by
densitometry. Quantitative data are expressed as mean ± SEM, n=5-10. *P < 0.05 vs.
db/db mice.

DISSISION
Consistent with the preventive effects of FGF1△HBS on early-stage db/db mice, here
we clearly demonstrated that FGF1△HBS normalized blood glucose levels, improved insulin
sensitivity and markedly prevented liver injury in these late-stage db/db mice, indicated by
decreased hepatic TG levels, ALT and AST activity, and inflammatory marker expression
(Fig. 14-15). These results validated the protection of FGF1△HBS against the late-stage
NAFLD. Importantly, the mechanism studies showed that FGF1△HBS effectively activated
AMPK-mediated Nrf2-antioxidative stress signaling pathways and lipid metabolic signaling
pathways in those chronic liver diseases of aged db/db mice (Fig.16 and Fig. 17).
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Combined with the preventive data found above, we demonstrate that FGF1△HBS
could be promising candidate drug for prevention and therapeutic against NAFLD in T2D
without the undesired mitogenic side effects of FGF1WT.
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CHAPTER V
OVERALL DISCUSSION AND CONCLUSIONS

Several studies have indicated the potential metabolic function of FGF1 in diabetes
and steatosis. However, the use of FGF1 in the treatment of metabolic syndrome is still
limited due to its undefined mechanism and its potential risk of tumorigenesis. The goals
of the study in this dissertation are to evaluate the preventive and therapeutic effects of a
novel FGF1 non-mitogenic variant, FGF1ΔHBS, on NAFLD in T2D, and to explore the
underlying mechanisms. The outcomes of these studies strongly suggest that FGF1ΔHBS
can be a promising therapeutic agent for NAFLD therapy in T2D. Our results can be
summarized as follows:
● FGF1△HBS treatment prevented the liver injury and inhibited the hepatic oxidative
stress via activation of Nrf2-mediated antioxidative signaling pathways.
● FGF1△HBS treatment reduced hepatic lipid accumulation by inhibiting lipogenesis
and increasing fatty acid oxidation mediated via AMPK signaling pathways.
● Nrf2 activation played an important role for the anti-oxidative effect of FGF1, but
was not required for the protective effects of FGF1 against palmitate-induced
lipid metabolic disorder in HepG2 cells.
● AMPK played a critical role in FGF1 protection against Pal-induced oxidative
stress and lipid disorder possibly via activating Nrf2-mediated antioxidative
pathway and inhibiting SREBP-1-mediated lipid metabolic pathway in primary
hepatocytes.
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● FGF1△HBS completely reversed the phenotype of NAFLD along with activation
on Nrf2 and AMPK signaling pathways in late-stage T2D.

Overall discussion
As discussed above, our study demonstrated that FGF1△HBS is a promising
therapeutic agent in the prevention/treatment of NAFLD in T2D. However, there are
several limitations and questions remain to be answered. Some special findings should
be further annotated:

Whether the effect of FGF1 on NAFLD depends on its glucose lowering capability?
In this dissertation, a typical type 2 diabetes model, db/db mice are chosen to
explore the functions and mechanisms of FGF1 in NAFLD. FGF1△HBS treatment not only
reverse the hepatic injuries but also significantly lower the blood glucose to the normal
levels in db/db mice. One of the significant questions is if the effect of FGF1 on NAFLD
depends on its glucose lowering ability. There are several possible explanations:
a) To exclude the influence of blood glucose in vivo, our study used palmitatetreated hepatic cell culture in vitro models, which could determine the direct effect of FGF1
on hepatocyte. The results suggested that FGF1 protected against the palmitate-induced
oxidative stress and lipid disorder in both HepG2 cells and primary hepatocytes.
b) Our previous study demonstrated that FGF1 could ameliorate diabetic
nephropathy in both T1D and T2D even without any effect on the blood glucose levels in
T1D, suggesting that FGF1 protection against DN was independent of its blood glucose
lowering capacity(26).
c) As described in the OVERVIEW, several studies have showed that FGF1
exhibited protective effect against other diabetic complications in T1D without lowering the
blood glucose. For examples, FGF1 ameliorated left ventricle dysfunction and reduced the
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myocardial apoptosis in diabetic cardiomyopathy of STZ-induced T1D(52,

. FGF1

53)

promoted wound healing in diabetic ulcer of T1D by enhancing the expression of TGF-β
and PCNA and inhibiting oxidative stress(41).
Based on these studies, we speculate that the effect of FGF1△HBS on NAFLD is
related to, but independent of its glucose lowering capability. NAFLD models without
hyperglycemia should be considered to determine the direct effects and mechanisms of
FGF1△HBS in fatty liver diseases in future studies.

Whether FGF1 directly regulates hepatic de novo lipogenesis and fatty acid βoxidation in the protection against NAFLD?
Several studies have demonstrated that exogenous excessive palmitate induced
hepatic lipotoxicity, which was characterized by ROS accumulation, mitochondrial
dysfunction, damaged fatty acid oxidation, and increased triglyceride accumulation(178, 179).
This dissertation utilized this model to mimic diabetes-induced lipotoxicity in liver in T2D.
Our results showed that both FGF1WT and FGF1△HBS prevented Pal-induced oxidative
stress via upregulating Nrf2 mediated antioxidative signaling pathway and prevented Palinduced lipid metabolic disorder via increasing fatty acid oxidation and inhibiting the
lipogenic signaling pathways.
Although this dissertation and other previous studies have shown Pal treatment
could induce hepatic lipogenesis and inhibit fatty acid β-oxidation(159, 180, 181), this Palinduced model is not a direct and specific in vitro model to define the mechanism of FGF1
in lipid metabolism, especially in de novo lipogenesis. Hepatic de novo lipogenesis is the
biosynthetic process of fatty acids from acetyl‐CoA subunits that are produced from the
dietary glucose, high‐carbohydrate or fructose(182). Many key enzymes and transcription
factors, such as ACC, FAS, SREBP-1, are strongly involved in the de novo lipogenesis by
converting the acetyl‐CoA into malonyl-CoA, subsequently, to fatty acids. Therefore,
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glucose is the main and direct lipogenic substrate that drives de novo lipogenesis(66) and
nutritionally regulate the key enzymes and transcription factors(183, 184). To fully understand
the mechanism of FGF1 in regulating lipid metabolism, the high glucose plus insulin cell
culture models(155, 185) should be considered in future studies.

Whether AMPK plays a critical role in FGF1 protects against NAFLD in vivo?
AMPK is a well-known central regulator and therapeutic target for many metabolic
diseases. In addition to activating metabolic processes, AMPK inhibits inﬂammation, ER
and oxidative stress, and activates autophagy(167). The question becomes whether AMPK
plays a critical role in FGF1 protection against NAFLD in vivo.
a) The metabolic functions of FGF1 are newly discovered and its target organs
and/or tissues have not been clearly defined. This dissertation firstly indicated that FGF1
significantly activated the phosphorylation of hepatic AMPK and its downstream genes in
vivo and in vitro. Reference to the well-studied endocrine growth factor FGF21, its energy
metabolic functions are strongly associated with AMPK pathways(72, 186).
b) The present study also indicated that FGF1 inhibited the oxidative stress in
NAFLD via activating Nrf2-mediated antioxidative signaling pathway. Recent studies
suggested that Nrf2 is not only an important anti-oxidative factor, but also a potential target
to the metabolic syndrome(137, 138). Distinguishing the functions between AMPK and Nrf2
is important to define the targets for FGF1. According to previous studies, Nrf2 and AMPK
can interact to regulate each other at different pathological and physiological conditions(87,
. According to our in vitro study, knockdown of AMPK in hepatocyte abolished

117, 165, 187)

both Nrf2-mediated anti-oxidative signaling pathway and SREBP-1-mediated lipid
metabolic pathway, suggesting that AMPK is an upstream factor of Nrf2 and SREBP-1 for
FGF1 protection against Pal-induce hepatic lipotoxicity. To elucidate the critical role of
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AMPK in FGF1 protection against NAFLD, liver-specific AMPK knockout model could be
considered in future studies.

Which FGF receptor mediates the function of FGF1△HBS in the activation of AMPK
against NAFLD?
FGFs carry out their diverse functions by binding and activating specific FGF
receptors (FGFRs)(12). In addition, AMPK as a central metabolic sensor can be regulated
by many major upstream kinases, such as liver kinase B1 (LKB1), calmodulin-dependent
protein kinase kinase 2 (CaMKK2) and TGF-β-activated kinase (TAK1)(188, 189). The goal
of present study was not to define the binding partners of FGF1△HBS. However, several
explanations are possible based on previous studies:
a) As introduced in the OVERVIEW, FGF1 is considered the universal ligand that
actively bind to the four different FGFRs (FGFR1–FGFR4)(9,

. FGFR1–FGFR4 are

10)

positively expressed in normal liver(190) and these receptors-mediated signaling pathways
are essential for liver pathophysiology(191). In hepatocytes, FGFR4 is the most abundant
FGFR that acts as a regulator of bile acid homeostasis and protects liver from fibrosis(192).
Loss or overexpression of FGFR1, FGFR2 and FGFR3 in hepatocytes also strongly
impairs the liver homeostasis and regeneration(191, 193) (194).
b) Previous studies suggested that the endocrine FGF15/19 acts on the
FGFR4/βKlotho complex showing the beneficial effects on liver metabolism. however, it
also stimulated hepatocyte proliferation through an FGFR4-dependent mechanism(195).
Meanwhile, FGFR1c isoform is important for the in vivo actions of endocrine FGF21. A
previous study showed that the endocrine FGF21 activated the AMPK signaling pathway
in the target tissues through FGFR1/β-klotho signaling directly(196).
c) Recent study showed that the blood glucose-lowering effects of FGF1 were
mediated through FGFR1, FGF1 failed to lower glucose levels in the FGFR1 knockout
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mice(9). Consistent with this, a FGF1 analogue FGF1ΔNT (FGF1 L29–D155) similarly failed
to affect blood glucose levels in FGFR1 knockout mice(9), further supporting the notion that
FGFR1-mediated signaling is required for the glucose-lowering effects of parenteral
FGF1(9).
d) In our previous study, we found that compared to the FGF1WT, FGF1△HBS
diminished its ability to induce heparan sulfate-assisted FGFR1 dimerization and
activation, resulting in a diminished ability to induce FRS2 phosphorylation, the major
substrate of FGFRs, and the downstream ERK activation, in both adipoctyes and
hepatocytes(85).
Taken together, we speculate that FGFR1 is the major receptor mediating the
metabolic function of FGF1 in liver, as well as in adipose tissue, which needs to be verified
in future studies.

The optimal dose of FGF1△HBS
The dose-response results in our previous study clearly showed that an acute
injection of FGF1WT and FGF1△HBS at the dose of 0.5 mg/kg body weight significantly
lowered blood glucose levels, and this effect lasted up to to 24 hours in db/db mice without
further lowering effects by increasing the dose to 1 mg/kg body weight(85). Furthermore,
treatment of db/db mice with FGF1WT and FGF1△HBS at a dose of 0.5 mg/kg every other
day for 4 weeks resulted in the sustained glucose lowering and attenuating the hepatic
steatosis(85). Hence, FGF1△HBS delivery at the dose of 0.5mg/kg every other day was
applied in the present study. However, this dose might not be the optimal one for liver
protection, although we observed that FGF1△HBS at the dose of 0.5 mg/kg exhibited an
antisteatotic effect. To achieve the optimal effects and establish the fundamental dose
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regime for future FGF1△HBS clinical use, the dose- and time-dependent effects of FGF1△HBS
on the prevention and reversal of NAFLD need to be addressed in future studies.

Innovations
The innovations in this dissertation can be summarized as follows：
● FGF1△HBS can effectively prevent and reverse NAFLD by inhibiting oxidative stress
and regulating lipid metabolism in T2D.
● AMPK may be a novel therapeutic target for FGF1△HBS prevention and reversal of
NAFLD.
● The novel non-mitogenic variant FGF1△HBS may be an effective and safe
alternative of FGF1WT for the prevention and treatment of NAFLD and other diabetic
complications.

Limitations
As above discussed, several limitations should be clarified in this dissertation.
1) NAFLD model: to elucidate the direct functions and mechanisms of FGF1 in the
fatty liver, non-diabetic NAFLD models are needed in the future study.
2) Cell culture model: to understand the mechanism of FGF1 regulating lipid
metabolism, the high glucose plus insulin-induced cell model should be considered.
3) Hepatic AMPK inactive model: to dissect the critical role of AMPK in FGF1
protection against NAFLD, liver specific AMPK knockout model should be used.
4) Side effects: the safety for FGF1△HBS treatment of NAFLD should be evaluated
systemically.
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Future directions
● Mechanistic study: In addition to regulating lipid metabolism in NAFLD of T2D,
FGF1 is a potent insulin sensitizer that lowers the blood glucose and increases the insulin
sensitivity in diabetes. The understanding of how FGF1 increases insulin sensitivity, as
well as how FGF1 regulates glucose and lipid metabolism will be the key objects in our
future studies.
● Clinical translation: this dissertation demonstrates that the novel non-mitogenic
variant FGF1△HBS is a promising candidate drug to replace FGF1WT to treat NAFLD in T2D
without the risk of tumorigenesis. We will continually explore its potential for preventing
other metabolic syndrome and their complications, such as obesity, and diabetic
cardiovascular diseases in animals and even apply for a phase I clinical observation for
the prevention of NAFLD for T2D patients.

Conclusion
In summary, our findings indicate that, in addition to its potent glucose-lowering and
insulin-sensitizing effects, the novel non-mitogenic variant FGF1△HBS has not only
preventive and but therapeutic effects on NAFLD in T2D via effectively inhibiting oxidative
stress and improving lipid metabolism, which shows a great potential to replace the use
of FGF1WT to treat NAFLD in diabetes. Importantly, our studies provide new insight into
the mechanisms by which FGF1△HBS prevents hepatic oxidative stress and steatosis in
T2D. AMPK, that activates Nrf2-mediated antioxidative pathway and inhibits SREBP-1mediated lipid metabolic pathway, is a critical target for FGF1 protection against NAFLD
in T2D (Fig. 18). From our perspective, a full understanding of FGF1 function in metabolic
disorders requires further investigation of the multiple aspects of roles of AMPK or other
molecular targets in these pathophysiological processes. This project provides
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fundamental evidence for FGF1 as a novel therapeutic approach to prevention of NAFLD
via activating hepatic AMPK.

Fig. 18 A mechanistic illustration of FGF1 preventing diabetes-induced hepatic
oxidative stress and lipid disorder via activating AMPK signaling pathways. FGF1 activates
AMPK-mediated lipid metabolism and anti-oxidative stress signaling via inhibiting the lipid
accumulation and upregulating lipid oxidation, as well as Nrf2-mediated anti-oxidative
signaling pathway, thus prevents diabetes-induced hepatic lipid disorder and oxidative
stress, resulting in prevention and therapeutic against NAFLD in T2D.

71

REFERENCES
1.
Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and
therapy. Nat Rev Drug Discov 2009;8:235-253.
2.
Ohta H, Itoh N. Roles of FGFs as Adipokines in Adipose Tissue Development,
Remodeling, and Metabolism. Front Endocrinol (Lausanne) 2014;5:18.
3.
Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family.
Dev Dyn 2008;237:18-27.
4.
Wang WP, Lehtoma K, Varban ML, Krishnan I, Chiu IM. Cloning of the gene
coding for human class 1 heparin-binding growth factor and its expression in fetal
tissues. Mol Cell Biol 1989;9:2387-2395.
5.
Chiu IM, Liu Y, Payson RA. Isolation of yeast artificial chromosomes containing
the entire transcriptional unit of the human FGF1 gene: a 720-kb contig spanning human
chromosome 5q31.3-->q32. Cancer Genet Cytogenet 1998;106:1-10.
6.
Madiai F, Hackshaw KV, Chiu IM. Cloning and characterization of the mouse Fgf1 gene. Gene 1996;179:231-236.
7.
Madiai F, Hackshaw KV, Chiu IM. Characterization of the entire transcription unit
of the mouse fibroblast growth factor 1 (FGF-1) gene. Tissue-specific expression of the
FGF-1.A mRNA. J Biol Chem 1999;274:11937-11944.
8.
Sarabipour S, Hristova K. Mechanism of FGF receptor dimerization and
activation. Nat Commun 2016;7:10262.
9.
Suh JM, Jonker JW, Ahmadian M, Goetz R, Lackey D, Osborn O, Huang Z, et al.
Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature
2014;513:436-439.
10.
Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL. Crystal structure of
fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature
2000;407:1029-1034.
11.
Raju R, Palapetta SM, Sandhya VK, Sahu A, Alipoor A, Balakrishnan L, Advani
J, et al. A Network Map of FGF-1/FGFR Signaling System. J Signal Transduct
2014;2014:962962.
12.
Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the
lens of structural biology. Nat Rev Mol Cell Biol 2013;14:166-180.

72

13.
Lopez JJ, Edelman ER, Stamler A, Hibberd MG, Prasad P, Thomas KA, DiSalvo
J, et al. Angiogenic potential of perivascularly delivered aFGF in a porcine model of
chronic myocardial ischemia. Am J Physiol 1998;274:H930-936.
14.
Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of
neoangiogenesis in ischemic myocardium by human growth factors: first clinical results
of a new treatment of coronary heart disease. Circulation 1998;97:645-650.
15.
Palmen M, Daemen MJ, De Windt LJ, Willems J, Dassen WR, Heeneman S,
Zimmermann R, et al. Fibroblast growth factor-1 improves cardiac functional recovery
and enhances cell survival after ischemia and reperfusion: a fibroblast growth factor
receptor, protein kinase C, and tyrosine kinase-dependent mechanism. J Am Coll
Cardiol 2004;44:1113-1123.
16.
Maquet V, Martin D, Scholtes F, Franzen R, Schoenen J, Moonen G, Jer me R.
Poly(D,L-lactide) foams modified by poly(ethylene oxide)-block-poly(D,L-lactide)
copolymers and a-FGF: in vitro and in vivo evaluation for spinal cord regeneration.
Biomaterials 2001;22:1137-1146.
17.
Cheng H, Cao Y, Olson L. Spinal cord repair in adult paraplegic rats: partial
restoration of hind limb function. Science 1996;273:510-513.
18.
Huang MC, Chen KC, Chuang TY, Chang WC, Lee LS, Huang WC, Cheng H.
Cervical root repair in adult rats after transection: recovery of forelimb motor function.
Exp Neurol 2003;180:101-109.
19.
Tan Y, Wang KY, Wang N, Li G, Liu D. Ectopic expression of human acidic
fibroblast growth factor 1 in the medicinal plant, Salvia miltiorrhiza, accelerates the
healing of burn wounds. BMC Biotechnol 2014;14:74.
20.
Jonker JW, Suh JM, Atkins AR, Ahmadian M, Li P, Whyte J, He M, et al. A
PPARgamma-FGF1 axis is required for adaptive adipose remodelling and metabolic
homeostasis. Nature 2012;485:391-394.
21.
Liu JJ, Foo JP, Liu S, Lim SC. The role of fibroblast growth factor 21 in diabetes
and its complications: A review from clinical perspective. Diabetes Res Clin Pract
2015;108:382-389.
22.
Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev
2013;93:137-188.
23.
Alam U, Asghar O, Azmi S, Malik RA. General aspects of diabetes mellitus.
Handb Clin Neurol 2014;126:211-222.
24.
Scarlett JM, Rojas JM, Matsen ME, Kaiyala KJ, Stefanovski D, Bergman RN,
Nguyen HT, et al. Central injection of fibroblast growth factor 1 induces sustained
remission of diabetic hyperglycemia in rodents. Nat Med 2016;22:800-806.
25.
Huang Z, Lu M, Zhu G, Gao H, Xie L, Zhang X, Ye C, et al. Acceleration of
diabetic-wound healing with PEGylated rhaFGF in healing-impaired streptozocin diabetic
rats. Wound Repair Regen 2011;19:633-644.
73

26.
Liang G, Song L, Chen Z, Qian Y, Xie J, Zhao L, Lin Q, et al. Fibroblast growth
factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism. Kidney
Int 2017.
27.
Perry RJ, Lee S, Ma L, Zhang D, Schlessinger J, Shulman GI. FGF1 and FGF19
reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat
Commun 2015;6:6980.
28.
Alberti KG, Zimmet P. Global burden of disease--where does diabetes mellitus fit
in? Nat Rev Endocrinol 2013;9:258-260.
29.
Ahlqvist E, van Zuydam NR, Groop LC, McCarthy MI. The genetics of diabetic
complications. Nat Rev Nephrol 2015;11:277-287.
30.
Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB.
Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care
2014;37:651-658.
31.

Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003;361:1545-1551.

32.
Amin N, Doupis J. Diabetic foot disease: From the evaluation of the "foot at risk"
to the novel diabetic ulcer treatment modalities. World J Diabetes 2016;7:153-164.
33.
Naves CC. The Diabetic Foot: A Historical Overview and Gaps in Current
Treatment. Adv Wound Care (New Rochelle) 2016;5:191-197.
34.
Blakytny R, Jude E. The molecular biology of chronic wounds and delayed
healing in diabetes. Diabet Med 2006;23:594-608.
35.
Hilton JR, Williams DT, Beuker B, Miller DR, Harding KG. Wound dressings in
diabetic foot disease. Clin Infect Dis 2004;39 Suppl 2:S100-103.
36.
Edmonds M, Foster A. The use of antibiotics in the diabetic foot. Am J Surg
2004;187:25s-28s.
37.
Thomas KA, Rios-Candelore M, Gimenez-Gallego G, DiSalvo J, Bennett C,
Rodkey J, Fitzpatrick S. Pure brain-derived acidic fibroblast growth factor is a potent
angiogenic vascular endothelial cell mitogen with sequence homology to interleukin 1.
Proc Natl Acad Sci U S A 1985;82:6409-6413.
38.
Mellin TN, Cashen DE, Ronan JJ, Murphy BS, DiSalvo J, Thomas KA. Acidic
Fibroblast Growth Factor Accelerates Dermal Wound Healing in Diabetic Mice. Journal
of Investigative Dermatology 1995;104:850-855.
39.
Matuszewska B, Keogan M, Fisher DM, Soper KA, Hoe CM, Huber AC, Bondi
JV. Acidic fibroblast growth factor: evaluation of topical formulations in a diabetic mouse
wound healing model. Pharm Res 1994;11:65-71.
40.
Blaber SI, Diaz J, Blaber M. Accelerated healing in NONcNZO10/LtJ type 2
diabetic mice by FGF-1. Wound Repair Regen 2015;23:538-549.
74

41.
Xie L, Zhang M, Dong B, Guan M, Lu M, Huang Z, Gao H, et al. Improved
refractory wound healing with administration of acidic fibroblast growth factor in diabetic
rats. Diabetes Res Clin Pract 2011;93:396-403.
42.
Wang W, Lin S, Xiao Y, Huang Y, Tan Y, Cai L, Li X. Acceleration of diabetic
wound healing with chitosan-crosslinked collagen sponge containing recombinant
human acidic fibroblast growth factor in healing-impaired STZ diabetic rats. Life Sci
2008;82:190-204.
43.
Severson DL. Diabetic cardiomyopathy: recent evidence from mouse models of
type 1 and type 2 diabetes. Can J Physiol Pharmacol 2004;82:813-823.
44.
Papa G, Degano C, Iurato MP, Licciardello C, Maiorana R, Finocchiaro C.
Macrovascular complication phenotypes in type 2 diabetic patients. Cardiovasc Diabetol
2013;12:20.
45.
Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am
Coll Cardiol 2012;59:635-643.
46.
Gilca GE, Stefanescu G, Badulescu O, Tanase DM, Bararu I, Ciocoiu M. Diabetic
Cardiomyopathy: Current Approach and Potential Diagnostic and Therapeutic Targets. J
Diabetes Res 2017;2017:1310265.
47.
Waltenberger J. Modulation of growth factor action: implications for the treatment
of cardiovascular diseases. Circulation 1997;96:4083-4094.
48.
Casscells W, Speir E, Sasse J, Klagsbrun M, Allen P, Lee M, Calvo B, et al.
Isolation, characterization, and localization of heparin-binding growth factors in the heart.
J Clin Invest 1990;85:433-441.
49.
Speir E, Tanner V, Gonzalez AM, Farris J, Baird A, Casscells W. Acidic and
basic fibroblast growth factors in adult rat heart myocytes. Localization, regulation in
culture, and effects on DNA synthesis. Circ Res 1992;71:251-259.
50.
Wu X, Su Z, Li X, Zheng Q, Huang Y, Yuan H. High-level expression and
purification of a nonmitogenic form of human acidic fibroblast growth factor in
Escherichia coli. Protein Expr Purif 2005;42:7-11.
51.
Zhang C, Zhang L, Chen S, Feng B, Lu X, Bai Y, Liang G, et al. The prevention
of diabetic cardiomyopathy by non-mitogenic acidic fibroblast growth factor is probably
mediated by the suppression of oxidative stress and damage. PLoS One
2013;8:e82287.
52.
Zhao YZ, Zhang M, Wong HL, Tian XQ, Zheng L, Yu XC, Tian FR, et al. Prevent
diabetic cardiomyopathy in diabetic rats by combined therapy of aFGF-loaded
nanoparticles and ultrasound-targeted microbubble destruction technique. J Control
Release 2016;223:11-21.
53.
Zhang M, Yu WZ, Shen XT, Xiang Q, Xu J, Yang JJ, Chen PP, et al. Advanced
Interfere Treatment of Diabetic Cardiomyopathy Rats by aFGF-Loaded Heparin-Modified
Microbubbles and UTMD Technique. Cardiovasc Drugs Ther 2016;30:247-261.
75

54.
Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney
disease: world wide difference of prevalence and risk factors. J Nephropharmacol
2016;5:49-56.
55.
Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T.
Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care
2005;28:164-176.
56.
Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic
mechanisms of diabetic nephropathy. Annu Rev Pathol 2011;6:395-423.
57.
Maric-Bilkan C. Obesity and diabetic kidney disease. Med Clin North Am
2013;97:59-74.
58.

Rabkin R. Diabetic nephropathy. Clin Cornerstone 2003;5:1-11.

59.
Floege J, Kriz W, Schulze M, Susani M, Kerjaschki D, Mooney A, Couser WG, et
al. Basic fibroblast growth factor augments podocyte injury and induces
glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest
1995;96:2809-2819.
60.
Guan X, Nie L, He T, Yang K, Xiao T, Wang S, Huang Y, et al. Klotho
suppresses renal tubulo-interstitial fibrosis by controlling basic fibroblast growth factor-2
signalling. J Pathol 2014;234:560-572.
61.
Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E, Bruijn JA. Gene
expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J
Kidney Dis 2004;43:636-650.
62.
Rossini M, Cheunsuchon B, Donnert E, Ma LJ, Thomas JW, Neilson EG, Fogo
AB. Immunolocalization of fibroblast growth factor-1 (FGF-1), its receptor (FGFR-1), and
fibroblast-specific protein-1 (FSP-1) in inflammatory renal disease. Kidney Int
2005;68:2621-2628.
63.
Tomaszewski M, Eales J, Denniff M, Myers S, Chew GS, Nelson CP,
Christofidou P, et al. Renal Mechanisms of Association between Fibroblast Growth
Factor 1 and Blood Pressure. J Am Soc Nephrol 2015;26:3151-3160.
64.
Ahn JM, Paik YH, Kim SH, Lee JH, Cho JY, Sohn W, Gwak GY, et al.
Relationship of liver stiffness and controlled attenuation parameter measured by
transient elastography with diabetes mellitus in patients with chronic liver disease. J
Korean Med Sci 2014;29:1113-1119.
65.
Kantartzis K, Machann J, Schick F, Fritsche A, Haring HU, Stefan N. The impact
of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia
2010;53:882-889.
66.
Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic
disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) 2009;116:539-564.

76

67.
Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic
steatohepatitis: pathophysiology and clinical implications. Gastroenterology
2012;142:711-725 e716.
68.
Barros BSV, Santos DC, Pizarro MH, del Melo LGN, Gomes MB. Type 1
Diabetes and Non-Alcoholic Fatty Liver Disease: When Should We Be Concerned? A
Nationwide Study in Brazil. Nutrients 2017;9.
69.
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, et
al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology
2003;37:917-923.
70.
64.

Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62:S47-

71.
Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, et al.
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem
2004;279:32345-32353.
72.
Nies VJ, Sancar G, Liu W, van Zutphen T, Struik D, Yu RT, Atkins AR, et al.
Fibroblast Growth Factor Signaling in Metabolic Regulation. Front Endocrinol
(Lausanne) 2015;6:193.
73.
Ye D, Wang Y, Li H, Jia W, Man K, Lo CM, Wang Y, et al. Fibroblast growth
factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating
peroxisome proliferator-activated receptor coactivator protein-1alpha-mediated
antioxidant capacity in mice. Hepatology 2014;60:977-989.
74.
Gong Q, Hu Z, Zhang F, Cui A, Chen X, Jiang H, Gao J, et al. Fibroblast growth
factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of
rapamycin complex 1 in mice. Hepatology 2016;64:425-438.
75.
Liu W, Struik D, Nies VJ, Jurdzinski A, Harkema L, de Bruin A, Verkade HJ, et al.
Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse
models of nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 2016;113:22882293.
76.
Khuu LA, Tayyari F, Sivak JM, Flanagan JG, Singer S, Brent MH, Huang D, et al.
Aqueous humour concentrations of TGF-beta, PLGF and FGF-1 and total retinal blood
flow in patients with early non-proliferative diabetic retinopathy. Acta Ophthalmol
2017;95:e206-e211.
77.
Skibba M, Zhang C, Jiang X, Xin Y, Cai L. Preventive effect of non-mitogenic
acidic fibroblast growth factor on diabetes-induced testicular cell death. Reprod Toxicol
2014;49:136-144.
78.
Zakrzewska M, Marcinkowska E, Wiedlocha A. FGF-1: from biology through
engineering to potential medical applications. Crit Rev Clin Lab Sci 2008;45:91-135.
79.

Kim TH, Eltohamy M, Kim M, Perez RA, Kim JH, Yun YR, Jang JH, et al.
77

Therapeutic foam scaffolds incorporating biopolymer-shelled mesoporous nanospheres
with growth factors. Acta Biomater 2014;10:2612-2621.
80.
Jiang B, Akar B, Waller TM, Larson JC, Appel AA, Brey EM. Design of a
composite biomaterial system for tissue engineering applications. Acta Biomater
2014;10:1177-1186.
81.
Okunieff P, Fenton BM, Zhang L, Kern FG, Wu T, Greg JR, Ding I. Fibroblast
growth factors (FGFS) increase breast tumor growth rate, metastases, blood flow, and
oxygenation without significant change in vascular density. Adv Exp Med Biol
2003;530:593-601.
82.
Henriksson ML, Edin S, Dahlin AM, Oldenborg PA, Oberg A, Van Guelpen B,
Rutegard J, et al. Colorectal cancer cells activate adjacent fibroblasts resulting in
FGF1/FGFR3 signaling and increased invasion. Am J Pathol 2011;178:1387-1394.
83.
Shi H, Fu C, Wang W, Li Y, Du S, Cao R, Chen J, et al. The FGF-1-specific
single-chain antibody scFv1C9 effectively inhibits breast cancer tumour growth and
metastasis. J Cell Mol Med 2014;18:2061-2070.
84.
Chen W, Yu M, Wang Y, Peng Y, Li X, Lam DM, Chen X, et al. Non-mitogenic
human acidic fibroblast growth factor reduces retinal degeneration induced by sodium
iodate. J Ocul Pharmacol Ther 2009;25:315-320.
85.
Huang Z, Tan Y, Gu J, Liu Y, Song L, Niu J, Zhao L, et al. Uncoupling the
Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer
Stability. Cell Rep 2017;20:1717-1728.
86.
Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity
and the metabolic syndrome. Proc Nutr Soc 2010;69:211-220.
87.
Yang Y, Li W, Liu Y, Sun Y, Li Y, Yao Q, Li J, et al. Alpha-lipoic acid improves
high-fat diet-induced hepatic steatosis by modulating the transcription factors SREBP-1,
FoxO1 and Nrf2 via the SIRT1/LKB1/AMPK pathway. J Nutr Biochem 2014;25:12071217.
88.
Gurzov EN, Tran M, Fernandez-Rojo MA, Merry TL, Zhang X, Xu Y, Fukushima
A, et al. Hepatic oxidative stress promotes insulin-STAT-5 signaling and obesity by
inactivating protein tyrosine phosphatase N2. Cell Metab 2014;20:85-102.
89.
Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis
of nonalcoholic steatohepatitis. Free Radic Biol Med 2012;52:59-69.
90.
Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in
multiple forms of insulin resistance. Nature 2006;440:944-948.
91.
Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y,
Nakayama O, et al. Increased oxidative stress in obesity and its impact on metabolic
syndrome. J Clin Invest 2004;114:1752-1761.

78

92.
Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and
oxidative stress in NAFLD/NASH. Free Radic Res 2013;47:869-880.
93.
Than NN, Newsome PN. Non-alcoholic fatty liver disease: when to intervene and
with what. Clin Med (Lond) 2015;15:186-190.
94.
Herman WH. The global agenda for the prevention of type 2 diabetes. Nutr Rev
2017;75:13-18.
95.
Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, Hirota Y, et al.
Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat
Genet 2008;40:1092-1097.
96.
Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, Andersen G, Ng DP,
et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian
and European populations. Nat Genet 2008;40:1098-1102.
97.
Arslanian SA. Type 2 diabetes mellitus in children: pathophysiology and risk
factors. J Pediatr Endocrinol Metab 2000;13 Suppl 6:1385-1394.
98.
Eppens MC, Craig ME, Cusumano J, Hing S, Chan AK, Howard NJ, Silink M, et
al. Prevalence of diabetes complications in adolescents with type 2 compared with type
1 diabetes. Diabetes Care 2006;29:1300-1306.
99.
Hillier TA, Pedula KL. Complications in young adults with early-onset type 2
diabetes: losing the relative protection of youth. Diabetes Care 2003;26:2999-3005.
100. Hurwitz Eller N, Netterstrom B. The intima media thickness and coronary risk
factors. Int Angiol 2001;20:118-125.
101. Reinehr T, Kiess W, Kapellen T, Wiegand S, Holl RW, Apv, Group DPVWS, et al.
Children with diabetes mellitus type 2 in Europe: an underserved population. Arch Dis
Child 2010;95:954.
102. Shah AS, Dolan LM, Kimball TR, Gao Z, Khoury PR, Daniels SR, Urbina EM.
Influence of duration of diabetes, glycemic control, and traditional cardiovascular risk
factors on early atherosclerotic vascular changes in adolescents and young adults with
type 2 diabetes mellitus. J Clin Endocrinol Metab 2009;94:3740-3745.
103. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, et
al. Association of glycaemia with macrovascular and microvascular complications of type
2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
104. Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. Hepatobiliary Surg
Nutr 2015;4:101-108.
105. Liu Z, Hartman YE, Warram JM, Knowles JA, Sweeny L, Zhou T, Rosenthal EL.
Fibroblast growth factor receptor mediates fibroblast-dependent growth in EMMPRINdepleted head and neck cancer tumor cells. Mol Cancer Res 2011;9:1008-1017.

79

106. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth
factor receptor activation. Cytokine Growth Factor Rev 2005;16:107-137.
107. Yeh BK, Igarashi M, Eliseenkova AV, Plotnikov AN, Sher I, Ron D, Aaronson SA,
et al. Structural basis by which alternative splicing confers specificity in fibroblast growth
factor receptors. Proc Natl Acad Sci U S A 2003;100:2266-2271.
108. Olsen SK, Li JY, Bromleigh C, Eliseenkova AV, Ibrahimi OA, Lao Z, Zhang F, et
al. Structural basis by which alternative splicing modulates the organizer activity of FGF8
in the brain. Genes Dev 2006;20:185-198.
109. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV,
Mohammadi M, et al. Tissue-specific expression of betaKlotho and fibroblast growth
factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J
Biol Chem 2007;282:26687-26695.
110. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R,
Eliseenkova AV, et al. BetaKlotho is required for metabolic activity of fibroblast growth
factor 21. Proc Natl Acad Sci U S A 2007;104:7432-7437.
111. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, et
al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature
2006;444:770-774.
112. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, Xu C,
et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast
growth factor 19 subfamily members. Mol Cell Biol 2007;27:3417-3428.
113. Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M, Schlessinger J.
Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1
and elucidation of their importance in receptor activation and signal transduction. Mol
Cell Biol 1996;16:977-989.
114. Gasser E, Moutos CP, Downes M, Evans RM. FGF1 - a new weapon to control
type 2 diabetes mellitus. Nat Rev Endocrinol 2017.
115. Brandes RP, Janiszewski M. Direct detection of reactive oxygen species ex vivo.
Kidney Int 2005;67:1662-1664.
116. Khoubnasabjafari M, Ansarin K, Jouyban A. Reliability of malondialdehyde as a
biomarker of oxidative stress in psychological disorders. Bioimpacts 2015;5:123-127.
117. Sid B, Glorieux C, Valenzuela M, Rommelaere G, Najimi M, Dejeans N, Renard
P, et al. AICAR induces Nrf2 activation by an AMPK-independent mechanism in
hepatocarcinoma cells. Biochem Pharmacol 2014;91:168-180.
118. Gu J, Cheng Y, Wu H, Kong L, Wang S, Xu Z, Zhang Z, et al. Metallothionein Is
Downstream of Nrf2 and Partially Mediates Sulforaphane Prevention of Diabetic
Cardiomyopathy. Diabetes 2017;66:529-542.

80

119. Muller YL, Bogardus C, Pedersen O, Baier L. A Gly482Ser missense mutation in
the peroxisome proliferator-activated receptor gamma coactivator-1 is associated with
altered lipid oxidation and early insulin secretion in Pima Indians. Diabetes 2003;52:895898.
120. Ponziani FR, Pecere S, Gasbarrini A, Ojetti V. Physiology and pathophysiology
of liver lipid metabolism. Expert Rev Gastroenterol Hepatol 2015;9:1055-1067.
121.

Rui L. Energy metabolism in the liver. Compr Physiol 2014;4:177-197.

122. Day EA, Ford RJ, Steinberg GR. AMPK as a Therapeutic Target for Treating
Metabolic Diseases. Trends Endocrinol Metab 2017;28:545-560.
123. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress.
Curr Biol 2014;24:R453-462.
124. Pham-Huy LA, He H, Pham-Huy C. Free radicals, antioxidants in disease and
health. Int J Biomed Sci 2008;4:89-96.
125. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res
2010;107:1058-1070.
126. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new
perspective on an old paradigm. Diabetes 1999;48:1-9.
127. Maritim AC, Sanders RA, Watkins JB, 3rd. Diabetes, oxidative stress, and
antioxidants: a review. J Biochem Mol Toxicol 2003;17:24-38.
128. Dandekar A, Mendez R, Zhang K. Cross talk between ER stress, oxidative
stress, and inflammation in health and disease. Methods Mol Biol 2015;1292:205-214.
129. Matough FA, Budin SB, Hamid ZA, Alwahaibi N, Mohamed J. The role of
oxidative stress and antioxidants in diabetic complications. Sultan Qaboos Univ Med J
2012;12:5-18.
130. Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y. The Role of
Oxidative Stress and Antioxidants in Liver Diseases. Int J Mol Sci 2015;16:26087-26124.
131. Silva-Gomes S, Santos AG, Caldas C, Silva CM, Neves JV, Lopes J, Carneiro F,
et al. Transcription factor NRF2 protects mice against dietary iron-induced liver injury by
preventing hepatocytic cell death. J Hepatol 2014;60:354-361.
132. Theodore M, Kawai Y, Yang J, Kleshchenko Y, Reddy SP, Villalta F, Arinze IJ.
Multiple nuclear localization signals function in the nuclear import of the transcription
factor Nrf2. J Biol Chem 2008;283:8984-8994.
133. Tamaki N, Cristina Orihuela-Campos R, Inagaki Y, Fukui M, Nagata T, Ito HO.
Resveratrol improves oxidative stress and prevents the progression of periodontitis via
the activation of the Sirt1/AMPK and the Nrf2/antioxidant defense pathways in a rat
periodontitis model. Free Radic Biol Med 2014;75:222-229.
81

134. Chen J, Zhang Z, Cai L. Diabetic cardiomyopathy and its prevention by nrf2:
current status. Diabetes Metab J 2014;38:337-345.
135. Dai X, Yan X, Zeng J, Chen J, Wang Y, Chen J, Li Y, et al. Elevating CXCR7
Improves Angiogenic Function of EPCs via Akt/GSK-3beta/Fyn-Mediated Nrf2 Activation
in Diabetic Limb Ischemia. Circ Res 2017;120:e7-e23.
136. Wu H, Kong L, Cheng Y, Zhang Z, Wang Y, Luo M, Tan Y, et al. Metallothionein
plays a prominent role in the prevention of diabetic nephropathy by sulforaphane via upregulation of Nrf2. Free Radic Biol Med 2015;89:431-442.
137. Xue P, Hou Y, Chen Y, Yang B, Fu J, Zheng H, Yarborough K, et al. Adipose
deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. Diabetes
2013;62:845-854.
138. Xu J, Kulkarni SR, Donepudi AC, More VR, Slitt AL. Enhanced Nrf2 activity
worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases
hepatic steatosis in leptin-deficient mice. Diabetes 2012;61:3208-3218.
139. Tanaka Y, Ikeda T, Yamamoto K, Ogawa H, Kamisako T. Dysregulated
expression of fatty acid oxidation enzymes and iron-regulatory genes in livers of Nrf2null mice. J Gastroenterol Hepatol 2012;27:1711-1717.
140. Tang W, Jiang YF, Ponnusamy M, Diallo M. Role of Nrf2 in chronic liver disease.
World J Gastroenterol 2014;20:13079-13087.
141. Chartoumpekis DV, Palliyaguru DL, Wakabayashi N, Fazzari M, Khoo NK,
Schopfer FJ, Sipula I, et al. Nrf2 deletion from adipocytes, but not hepatocytes,
potentiates systemic metabolic dysfunction after long-term high-fat diet-induced obesity
in mice. Am J Physiol Endocrinol Metab 2018.
142. Sekiya M, Hiraishi A, Touyama M, Sakamoto K. Oxidative stress induced lipid
accumulation via SREBP1c activation in HepG2 cells. Biochem Biophys Res Commun
2008;375:602-607.
143. Oliveira CP, da Costa Gayotto LC, Tatai C, Della Bina BI, Janiszewski M, Lima
ES, Abdalla DS, et al. Oxidative stress in the pathogenesis of nonalcoholic fatty liver
disease, in rats fed with a choline-deficient diet. J Cell Mol Med 2002;6:399-406.
144. Sykiotis GP, Habeos IG, Samuelson AV, Bohmann D. The role of the antioxidant
and longevity-promoting Nrf2 pathway in metabolic regulation. Curr Opin Clin Nutr Metab
Care 2011;14:41-48.
145. Ly LD, Xu S, Choi SK, Ha CM, Thoudam T, Cha SK, Wiederkehr A, et al.
Oxidative stress and calcium dysregulation by palmitate in type 2 diabetes. Exp Mol Med
2017;49:e291.
146. Zhang Y, Chen ML, Zhou Y, Yi L, Gao YX, Ran L, Chen SH, et al. Resveratrol
improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway.
Mol Nutr Food Res 2015;59:1443-1457.
82

147. Parhofer KG. The Treatment of Disorders of Lipid Metabolism. Dtsch Arztebl Int
2016;113:261-268.
148. Jaiswal M, Schinske A, Pop-Busui R. Lipids and lipid management in diabetes.
Best Pract Res Clin Endocrinol Metab 2014;28:325-338.
149. Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of
NAFLD/NASH. J Gastroenterol Hepatol 2013;28 Suppl 4:64-70.
150. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic
steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest
2008;118:829-838.
151. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in
nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006;91:4753-4761.
152. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local
and systemic insulin resistance resulting from hepatic activation of IKK-beta and NFkappaB. Nat Med 2005;11:183-190.
153.

Goldberg RB. Lipid disorders in diabetes. Diabetes Care 1981;4:561-572.

154. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that
maintains energy homeostasis. Nat Rev Mol Cell Biol 2012;13:251-262.
155. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, et al. AMPK
phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and
atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011;13:376-388.
156. Bujak AL, Crane JD, Lally JS, Ford RJ, Kang SJ, Rebalka IA, Green AE, et al.
AMPK activation of muscle autophagy prevents fasting-induced hypoglycemia and
myopathy during aging. Cell Metab 2015;21:883-890.
157. Viollet B, Andreelli F, Jorgensen SB, Perrin C, Geloen A, Flamez D, Mu J, et al.
The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin
sensitivity. J Clin Invest 2003;111:91-98.
158. Seo E, Park EJ, Joe Y, Kang S, Kim MS, Hong SH, Park MK, et al.
Overexpression of AMPKalpha1 Ameliorates Fatty Liver in Hyperlipidemic Diabetic Rats.
Korean J Physiol Pharmacol 2009;13:449-454.
159. Zhang HA, Yang XY, Xiao YF. AMPKalpha1 overexpression alleviates the
hepatocyte model of nonalcoholic fatty liver disease via inactivating p38MAPK pathway.
Biochem Biophys Res Commun 2016;474:364-370.
160. Foretz M, Ancellin N, Andreelli F, Saintillan Y, Grondin P, Kahn A, Thorens B, et
al. Short-term overexpression of a constitutively active form of AMP-activated protein
kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 2005;54:13311339.

83

161. Woods A, Williams JR, Muckett PJ, Mayer FV, Liljevald M, Bohlooly YM, Carling
D. Liver-Specific Activation of AMPK Prevents Steatosis on a High-Fructose Diet. Cell
Rep 2017;18:3043-3051.
162. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W,
Vasquez DS, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase
connects energy sensing to mitophagy. Science 2011;331:456-461.
163. Dugan LL, You YH, Ali SS, Diamond-Stanic M, Miyamoto S, DeCleves AE,
Andreyev A, et al. AMPK dysregulation promotes diabetes-related reduction of
superoxide and mitochondrial function. J Clin Invest 2013;123:4888-4899.
164. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy
through direct phosphorylation of Ulk1. Nat Cell Biol 2011;13:132-141.
165. Mo C, Wang L, Zhang J, Numazawa S, Tang H, Tang X, Han X, et al. The
crosstalk between Nrf2 and AMPK signal pathways is important for the anti-inflammatory
effect of berberine in LPS-stimulated macrophages and endotoxin-shocked mice.
Antioxid Redox Signal 2014;20:574-588.
166. Liu Y, Zhao C, Xiao J, Liu L, Zhang M, Wang C, Wu G, et al. Fibroblast growth
factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury.
Sci Rep 2016;6:31026.
167. Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance,
and the metabolic syndrome. J Clin Invest 2013;123:2764-2772.
168. Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet,
physical activity and exercise. J Hepatol 2017;67:829-846.
169. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of
NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies:
implications for prognosis and clinical management. J Hepatol 2015;62:1148-1155.
170. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2
diabetes mellitus--present and future perspectives. Nat Rev Endocrinol 2012;8:228-236.
171. Bourdel-Marchasson I, Schweizer A, Dejager S. Incretin therapies in the
management of elderly patients with type 2 diabetes mellitus. Hosp Pract (1995)
2011;39:7-21.
172. van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global
burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev
Rehabil 2010;17 Suppl 1:S3-8.
173. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, Huang ES, et al.
Diabetes in older adults. Diabetes Care 2012;35:2650-2664.
174. Lakey WC, Barnard K, Batch BC, Chiswell K, Tasneem A, Green JB. Are current
clinical trials in diabetes addressing important issues in diabetes care? Diabetologia
2013;56:1226-1235.
84

175. Fonseca VA. Defining and characterizing the progression of type 2 diabetes.
Diabetes Care 2009;32 Suppl 2:S151-156.
176. Schievink B, Kropelin T, Mulder S, Parving HH, Remuzzi G, Dwyer J, Vemer P,
et al. Early renin-angiotensin system intervention is more beneficial than late intervention
in delaying end-stage renal disease in patients with type 2 diabetes. Diabetes Obes
Metab 2016;18:64-71.
177. Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver
Disease. Int J Mol Sci 2016;17.
178. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol
2005;42:928-940.
179. Egnatchik RA, Leamy AK, Noguchi Y, Shiota M, Young JD. Palmitate-induced
activation of mitochondrial metabolism promotes oxidative stress and apoptosis in
H4IIEC3 rat hepatocytes. Metabolism 2014;63:283-295.
180. Zhou Y, Yu S, Cai C, Zhong L, Yu H, Shen W. LXRa participates in the
mTOR/S6K1/SREBP-1c signaling pathway during sodium palmitate-induced lipogenesis
in HepG2 cells. Nutr Metab (Lond) 2018;15:31.
181. Kim DI, Park MJ, Lim SK, Park JI, Yoon KC, Han HJ, Gustafsson JA, et al.
PRMT3 regulates hepatic lipogenesis through direct interaction with LXRalpha. Diabetes
2015;64:60-71.
182. Sanders FW, Griffin JL. De novo lipogenesis in the liver in health and disease:
more than just a shunting yard for glucose. Biol Rev Camb Philos Soc 2016;91:452-468.
183. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete
program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:11251131.
184. Goldstein JL, Brown MS. From fatty streak to fatty liver: 33 years of joint
publications in the JCI. J Clin Invest 2008;118:1220-1222.
185. Matsuzaka T, Shimano H, Yahagi N, Amemiya-Kudo M, Okazaki H, Tamura Y,
Iizuka Y, et al. Insulin-independent induction of sterol regulatory element-binding protein1c expression in the livers of streptozotocin-treated mice. Diabetes 2004;53:560-569.
186. Chau MD, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21
regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc
Natl Acad Sci U S A 2010;107:12553-12558.
187. Zimmermann K, Baldinger J, Mayerhofer B, Atanasov AG, Dirsch VM, Heiss EH.
Activated AMPK boosts the Nrf2/HO-1 signaling axis--A role for the unfolded protein
response. Free Radic Biol Med 2015;88:417-426.
188. Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signalling. J Mol
Endocrinol 2010;44:87-97.
85

189. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth
control in tumour suppression. Nat Rev Cancer 2009;9:563-575.
190. Hughes SE. Differential expression of the fibroblast growth factor receptor
(FGFR) multigene family in normal human adult tissues. J Histochem Cytochem
1997;45:1005-1019.
191. Steiling H, Wustefeld T, Bugnon P, Brauchle M, Fassler R, Teupser D, Thiery J,
et al. Fibroblast growth factor receptor signalling is crucial for liver homeostasis and
regeneration. Oncogene 2003;22:4380-4388.
192. Bohm F, Speicher T, Hellerbrand C, Dickson C, Partanen JM, Ornitz DM, Werner
S. FGF receptors 1 and 2 control chemically induced injury and compound detoxification
in regenerating livers of mice. Gastroenterology 2010;139:1385-1396.
193. Sandhu DS, Baichoo E, Roberts LR. Fibroblast growth factor signaling in liver
carcinogenesis. Hepatology 2014;59:1166-1173.
194. Qiu WH, Zhou BS, Chu PG, Chen WG, Chung C, Shih J, Hwu P, et al. Overexpression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma.
World J Gastroenterol 2005;11:5266-5272.
195. Owen BM, Mangelsdorf DJ, Kliewer SA. Tissue-specific actions of the metabolic
hormones FGF15/19 and FGF21. Trends Endocrinol Metab 2015;26:22-29.
196. Salminen A, Kauppinen A, Kaarniranta K. FGF21 activates AMPK signaling:
impact on metabolic regulation and the aging process. J Mol Med (Berl) 2017;95:123131.

86

LIST OF ABBREVIATIONS
FGF1: Fibroblast Growth Factor 1
T2D: Type 2 Diabetes
NAFLD: Nonalcoholic Fatty Liver Disease
Nrf2: Nuclear Factor Erythroid 2-Related Factor 2
ROS: Reactive Oxygen Species
Pal: Palmitate
DHE: Dihydroethidium
MDA: Malondialdehyde
HO-1: Heme Oxygenase 1 (HO1)
NQO1: NAD(P)H Quinone Oxidase 1
CAT: Catalase
ALT: Alanine Aminotransferase
AST: Aspartate Aminotransferase
TG: Triglyceride
AMPK: AMP-activated protein kinase
ACC: Acetyl-CoA Carboxylase
SREBP-1: Sterol Regulatory Element-Binding Protein-1
FAS: Fatty Acid Synthase
SCD-1: Stearoyl-CoA desaturase-1
CPT-1α: Carnitine Palmitoyltransferase I α
PPARα: Peroxisome Proliferator-Activated Receptor α
PGC-1α: Peroxisome Proliferator-Activated Receptor-γ Coactivator α
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